University of North Dakota

UND Scholarly Commons
Theses and Dissertations

Theses, Dissertations, and Senior Projects

January 2015

The Relationship Between A Series Of Vitamin D
Levels And A Blood Glucose Level In Pregnant
Women In The Upper Midwest
Jeanine Louise Senti

Follow this and additional works at: https://commons.und.edu/theses
Recommended Citation
Senti, Jeanine Louise, "The Relationship Between A Series Of Vitamin D Levels And A Blood Glucose Level In Pregnant Women In
The Upper Midwest" (2015). Theses and Dissertations. 1960.
https://commons.und.edu/theses/1960

This Dissertation is brought to you for free and open access by the Theses, Dissertations, and Senior Projects at UND Scholarly Commons. It has been
accepted for inclusion in Theses and Dissertations by an authorized administrator of UND Scholarly Commons. For more information, please contact
zeineb.yousif@library.und.edu.

THE RELATIONSHIP BETWEEN A SERIES OF VITAMIN D LEVELS AND
A BLOOD GLUCOSE LEVEL IN PREGNANT WOMEN IN THE UPPER MIDWEST

by

Jeanine Louise Melstad Senti
Bachelor of Arts, University of North Dakota, 1979
Bachelor of Science, University of North Dakota, 1982
Master of Science, University of North Dakota, 1996

A Dissertation
Submitted to the Graduate Faculty
of the
University of North Dakota
In partial fulfillment of the requirements

for the degree of
Doctor of Philosophy

Grand Forks, North Dakota
December
2015

Copyright 2015 Jeanine Senti

ii

PERMISSION
Title

The Relationship Between a Series of Vitamin D Levels and a Blood
Glucose Level in Pregnant Women in the Upper Midwest

Department

College of Nursing and Professional Disciplines

Degree

Doctor of Philosophy

In presenting this dissertation in partial fulfillment of the requirements for a
graduate degree from the University of North Dakota, I agree that the library of this
University shall make it freely available for inspection. I further agree that permission
for extensive copying for scholarly purposes may be granted by the professor who
supervised my dissertation work or, in her absence, by the Chairperson of the department
or the dean of the School of Graduate Studies. It is understood that any financial gain
shall not be allowed without my written permission. It is also understood that due
recognition shall be given to me and to the University of North Dakota in any scholarly
use which may be made of any material in my dissertation.

Jeanine L. Melstad Senti
November 17, 2015

iv

TABLE OF CONTENTS
LIST OF FIGURES .......................................................................................................... xii
LIST OF TABLES ............................................................................................................ xii
ACKNOWLEDGMENTS ............................................................................................... xiv
ABSTRACT .......................................................................................................................xv
CHAPTER
I.

INTRODUCTION .............................................................................................1
Adaptations of Glucose Metabolism in Pregnancy ......................................2
Maternal Hyperglycemia in Pregnancy .......................................................3
Brief Overview of Vitamin D Metabolism ..................................................5
Hypovitaminosis-D ......................................................................................5
Calcidiol in Pregnant Women ......................................................................6
Calcidiol and Glucose Metabolism ..............................................................7
Serum Calcidiol and Glucose Metabolism in Pregnancy ............................7
Purpose Statement ........................................................................................8
Research Hypothesis ....................................................................................9
Research Questions ......................................................................................9
Problem Statement .......................................................................................9
Theoretical Framework ..............................................................................10
Significance of Study .................................................................................12
v

Assumptions...............................................................................................12
Summary of Key Points .............................................................................13
II.

REVIEW OF LITERATURE ..........................................................................15
Introduction ................................................................................................15
Definitions..................................................................................................15
Adaptations to Glucose Metabolism in Pregnancy ....................................18
Changing Insulin Metabolism ........................................................19
Factors Contributing to Insulin Resistance in Pregnancy ..............20
Maternal Hyperglycemia in Pregnancy .........................................20
Vitamin D Metabolism ..............................................................................23
Hypovitaminosis-D ........................................................................25
Prevalence of Hypovitaminosis-D .................................................26
Vitamin D in Pregnant Women......................................................27
Hypovitaminosis-D in Healthy Pregnant Women .........................28
Hypovitaminosis-D and Glucose Metabolism ...........................................29
Insulin Resistance and Hypovitaminosis-D in Pregnancy .............30
Hypovitaminosis-D in Early Pregnancy ........................................31
Hypovitaminosis-D in Mid Pregnancy ..........................................34
Hypovitaminosis-D in Late Pregnancy ..........................................36
Summary ................................................................................................................37

III.

METHODS ......................................................................................................39
Introduction ................................................................................................39
Research Design.........................................................................................40
vi

Population and Sample ..............................................................................41
Sampling Procedures .................................................................................41
Recruitment ................................................................................................42
Instrumentation ..........................................................................................43
Methods for Calcidiol Blood Sampling .........................................44
Laboratory Analysis for Serum Calcidiol Levels ..........................44
Laboratory Analysis of Blood Glucose..........................................45
Data Collection Procedures........................................................................46
Data Analysis .............................................................................................47
Research Questions ........................................................................48
Data Set ..........................................................................................48
Descriptive Data.............................................................................49
Multiple Regression Analysis ........................................................49
Independent Samples t-test ............................................................50
Trends in Serum Calcidiol Levels..................................................51
Association Between Confounding Variables ...............................51
Protection of Human Subjects ...................................................................51
IV. RESULTS ..............................................................................................................53
Introduction ................................................................................................53
Descriptive Statistics of the Sample Participants.......................................53
Age .................................................................................................54
Body Mass Index (BMI .................................................................54
Race of Study Participants .............................................................55
vii

Blood Glucose Levels ................................................................................58
Serum Calcidiol Levels ..............................................................................58
Prevalence of Hypovitaminosis-D in Sample ................................59
Range of Calcidiol Levels in Sample.............................................60
Scatterplot of Participants and Target Calcidiol Levels ................61
Serum Calcidiol Levels Over Time ...............................................62
Frequency Distribution of Calcidiol Levels Over Three
Collection Points ............................................................................62
Correlation in Calcidiol Levels ......................................................65
Research Questions and Analysis ..............................................................65
Correlation of Early Calcidiol With Mid Pregnancy
Glucose Level ................................................................................65
Correlation of Mid Pregnancy Calcidiol Level With Mid
Pregnancy Glucose Level ..............................................................66
Correlation of Late Pregnancy Calcidiol Level With Mid
Pregnancy Glucose Level ..............................................................66
Comparison of BG With Two Groups .......................................................67
Comparison of BG With Inadequate or Adequate Calcidiol in
Early Pregnancy .............................................................................67
Comparison of BG With Inadequate or Adequate Calcidiol in
Mid Pregnancy ...............................................................................68
Comparison of BG With Inadequate or Adequate Calcidiol in
Late Pregnancy...............................................................................69
Confounding Variables ..............................................................................70
Relationship Between BG and the Variables of BMI and Age .....71
Correlation Between BMI and Calcidiol Levels in Early,
Mid, and Late Pregnancy ...............................................................71
viii

Correlation Between Age and Calcidiol Level ..............................72
Summary ....................................................................................................72
V. DISCUSSION ........................................................................................................74
Introduction ................................................................................................74
Summary of the Study ...............................................................................74
Overview of the Problem ...............................................................74
Purpose Statement ..........................................................................75
Research Questions ........................................................................76
Review of the Methodology...........................................................77
Major Findings ...............................................................................78
Findings Related to the Literature..............................................................78
Maternal Age .................................................................................79
Body Mass Index ...........................................................................79
Blood Glucose................................................................................82
Effects of Hyperglycemia in Pregnancy ........................................82
Rationale for Choice of Blood Glucose Level ...............................82
Blood Glucose in This Study .........................................................82
Calcidiol .........................................................................................84
Recommended Daily Allowance for Calcidiol ..............................85
Rationale for Choice of Calcidiol Level ........................................85
Hypovitaminosis-D in North Dakota .............................................86
Influence of the Placenta on Calcidiol ...........................................87
Calcidiol in This Study ..................................................................88
ix

Serial Calcidiol Levels During Pregnancy .....................................88
Study Findings ...............................................................................89
Calcidiol and Blood Glucose in Pregnancy ...................................91
Multiple Linear Regression Analysis.............................................92
Relationship Between Calcidiol in Early Pregnancy
and Blood Glucose .........................................................................93
Relationship Between Calcidiol in Mid Pregnancy
and Blood Glucose .........................................................................95
Relationship Between Calcidiol in Late Pregnancy
And Blood Glucose ........................................................................98
Limitations .....................................................................................99
Calcidiol Testing Processes .........................................................100
Surprises...................................................................................................101
Conclusions ..........................................................................................................102
Implications for Action ........................................................................................103
Implications for Nursing Policy ...................................................103
Implications for Nursing Education .............................................104
Implications for Nursing Practice ................................................104
Recommendations for Further Research ......................................105
Concluding Remarks....................................................................106
APPENDICES .................................................................................................................108
Appendix A IRB Board Approvals ..........................................................109
Appendix B Consent Form ......................................................................111
Appendix C Medical Record Abstraction Tool .......................................114
x

Appendix D EIA Kit ................................................................................128
REFERENCES ................................................................................................................136

xi

LIST OF FIGURES
Figure

Page

1.

Glucose transport in placenta to fetus ....................................................................19

2.

Vitamin D metabolism ...........................................................................................25

3.

Recruitment and collection of data ........................................................................43

4.

Distribution of age in sample .................................................................................54

5.

Distribution of BMI in sample ...............................................................................55

6.

Race of sample and of North Dakota population ...................................................56

7.

Race of sample, North Dakota population, and of the United States ....................56

8.

Distribution of blood glucose at 24-28 weeks of gestation in sample ...................59

9.

Number of participants by calcidiol level greater or less than 75 nmol/L .............60

10.

Serum calcidiol levels for each participant at each time point ..............................61

11.

Mean of calcidiol levels at each time point (VitD-early, VitD-mid,
and VitD-late ..........................................................................................................62

12.

Distribution of serum calcidiol levels at 10-14 weeks gestation (VitD-early) ......63

13.

Distribution of serum calcidiol levels at 22-26 weeks gestation (VitD-mid) ........63

14.

Distribution of calcidiol levels at 32-26 weeks gestation (VitD-late) ...................64

15.

Distribution of all calcidiol levels in the sample and normal curve ......................64

16.

Rates of hyperglycemia in the study sample compared to PRAMS results
for North Dakota and the United States .................................................................83

17.

Calcidiol levels at three points in pregnancy .........................................................90
xii

LIST OF TABLES
Table

Page

1.

Description of Variables and Measurements ............................................................47

2.

Age and Body Mass Index ........................................................................................54

3.

Race of Sample and Population ................................................................................57

4.

Summary of Study Sample Findings for Blood Glucose ..........................................58

5.

Summary of Study Sample Findings of Calcidiol ....................................................61

6.

Pearson Correlation Showing the Trend in Calcidiol Levels....................................65

7.

R Square of Analysis of VitD-early, VitD-mid, VitD-late With BG When
Controlling for Age and BMI ...................................................................................67

8.

Mean Blood Glucose (BG) in mg/dl for Two Groups at 10-14
Weeks Gestation .......................................................................................................68

9.

Mean Blood Glucose (BG) for Two Groups at 22-26 Weeks Gestation ..................69

10.

Mean BG for Two Groups at 32-26 Weeks Gestation ..............................................70

11.

Correlations All Factors ............................................................................................72

12.

Comparison of Recommended Serum Calcidiol Levels for Pregnant
Women Ages 18-50 Years ........................................................................................86

13.

Research Findings of Calcidiol Levels at More Than One Point in Pregnancy .......90

xiii

ACKNOWLEDGMENTS
I wish to express my sincere appreciation to the members of my advisory
committee for their guidance and support during my time in the doctoral program at the
University of North Dakota. Dr. Jody Ralph for your guidance, encouragement, and
support, and for being such a wonderful mentor. You were amazing; the best “guide on
the side” a graduate student could have and I am eternally grateful. Dr. Cindy Anderson
for your expertise, direction, willingness to share your knowledge, and for being such a
great example of a nurse scientist. You made it possible for me to start and complete this
journey. Dr. Steve LeMire who not only taught me statistics, but also taught me how to
be a better teacher and how to write for publication. From the very first class, you gave
tips for success in graduate school. Dr. Darla Adams with your calm, supportive
presence every step along the way. Dr. Brian Higgerson who willingly stepped in and
contributed his insight and support.
I’d also like to acknowledge my family. My dear husband, Bruce, who watches
out for me with encouragement and his continual belief that I could achieve this personal
goal. My thanks to my children who cheered me on and to my grandchildren who make
me smile. And, finally, my mother and father who taught me the value and joy of
education.

xiv

Dedicated in loving memory of my mother,
Wilma Ruth Kalvig Melstad,
who inspired me with her lifelong love of learning.

ABSTRACT
Hyperglycemia during pregnancy is associated with adverse outcomes for both
mother and offspring. In order to facilitate glucose delivery to the fetus, insulin
resistance increases as gestation progresses which results in hyperglycemia if the
mother’s body is unable to compensate by producing adequate insulin in response to
these changes in glucose metabolism. Evidence suggests that calcidiol (vitamin D)
influences insulin sensitivity and glucose metabolism in the non-pregnant population yet
there are inconsistent findings on the effects of calcidiol on maternal glucose levels
during pregnancy. A secondary analysis was completed on a de-identified data set. The
original prospective study included a convenience sample of 52 nulliparous women from
a community in the upper Midwestern United States. Serum vitamin D levels were
obtained through laboratory measures at three predetermined points during pregnancy.
Medical record abstraction provided blood glucose levels in mid-pregnancy and height
and weight to calculate body mass index (BMI) at the beginning of pregnancy. Eightyone percent of the participants had hypovitaminosis-D at some point during pregnancy
and 67% had hypovitaminosis-D at all three points during pregnancy. Multiple
regression analysis was completed to examine the relationship between calcidiol levels
and blood glucose levels. A t-test was performed to look for a difference between two
groups, those with adequate calcidiol levels and those with inadequate serum calcidiol
levels. There was no evidence of a statistically significant relationship between calcidiol
xv

levels at any of the three points and the blood glucose levels when controlling for the
known confounding variables of BMI and age (R square .084, .071, and .075
respectively). The high percentage of hypovitaminosis-D was believed to result in
inadequate variance in this sample to show a difference, if one does exist. There was a
statistically significant correlation among the three calcidiol levels (p < .05). There was a
statistically significant inverse relationship between BMI and calcidiol levels in early
pregnancy (p < .05) and mid-pregnancy (p < .05). These findings suggest that many
women have hypovitaminosis-D in pregnancy, these levels are not improving during
pregnancy, and that women with a higher BMI may need additional vitamin D during
pregnancy.

xvi

CHAPTER I
INTRODUCTION
Hyperglycemia during pregnancy is associated with adverse outcomes for both
mothers and offspring (Pridjian & Benjamin, 2010) creating the need for interventions
which can reduce the harm from this condition. Research evidence suggests that vitamin
D influences glucose metabolism in the non-pregnant population (Forouhi, Luan, Cooper,
Boucher & Wareham, 2008; Hirani, 2011) and possibly in the pregnant population (Wei,
Qi, Luo & Fraser, 2013). More specifically, hypovitaminosis-D has been associated with
impaired glucose metabolism in conditions such as in type 2 diabetes (Alfonso, Liao,
Busta & Poretsky, 2009; Mathieu, Gysemans, Giulietti & Bouillon, 2005; Pittas et al.,
2006; Tohidi et al., 2013). There is a need to determine whether vitamin D similarly
influences glucose metabolism in pregnancy (Alzaim & Wood, 2013; McLeod et al.,
2011).
This chapter begins with a brief overview of the adaptations of glucose
metabolism in pregnancy and maternal hyperglycemia in pregnancy. It will be followed
by information on vitamin D metabolism, hypovitaminosis-D, and vitamin D in pregnant
women. Last, information specific to this study will be presented including the purpose
statement, hypothesis, problem statement, research questions, theoretical framework,
significance, and assumptions.

1

Adaptations of Glucose Metabolism in Pregnancy
Significant alterations occur in maternal physiology during pregnancy (Torgerson
& Curran, 2006). The placental hormones reprogram the maternal physiology to meet
the needs of the fetus and this includes a progressive increase in insulin resistance
(Barbour et al., 2007). The insulin resistance subsequently triggers the β-cells of the
pancreas to increase insulin production in order to maintain glucose homeostasis
(Evensen, 2012; Jelsma et al., 2013). In some cases, the pancreatic β-cells are not able to
adequately increase production which results in impaired glucose metabolism and
hyperglycemia (Gabbe et al., 2012, p. 892). Since the fetus obtains glucose from the
mother through the placenta, the adverse outcomes of maternal hyperglycemia during
pregnancy involve both the woman and the baby (Evensen, 2012; Lehnen, Zechner &
Haaf, 2013).
During pregnancy, insulin resistance progressively develops in the woman to
ensure the fetus is supplied with adequate glucose (Evenson, 2012). As the pregnancy
progresses, there is a gradual increase in post-prandial blood glucose levels (Gabbe et al.,
2012, p. 888) and the pancreatic β-cells need to respond by producing more insulin to
prevent hyperglycemia (McLeod et al., 2012). However, for some women, the β-cells of
the pancreas do not adequately increase the production of insulin to compensate (Jelsma
et al., 2013) which results in impaired glucose tolerance (Senti, Thiele & Anderson,
2012). These changes can be sufficiently diabetogenic for some of these women to result
in gestational diabetes (Senti et al., 2012).

2

Maternal Hyperglycemia in Pregnancy
Normally, pregnant women develop some insulin resistance during the second
and the third trimesters (McLeod et al., 2012) which can lead to hyperglycemia. Even
mildly increased maternal blood glucose levels can result in higher glucose delivery that
can affect the fetus (Fetita et al., 2006). The resulting hyperglycemia can have serious
health consequences for the mother and her children (Flack, Ross, Ho, & McElduff,
2010; Santamari, Cignini, Trapanese, & Bonalumi, 2011). Women who develop
hyperglycemia during pregnancy are at increased risk for early, induced labor, difficult
labor, and operative delivery (vacuum, forceps, or cesarean). Infants of mothers with
hyperglycemia are at increased risk for macrosomia, birth injury such as shoulder
dystocia or fractured clavicle, and medical complications after birth including
hypoglycemia, polycythemia, hypocalcemia, respiratory distress syndrome, and
hyperbilirubinemia (Santamari, Cignin, Trapanese, & Bonalumi, 2011). These conditions
may require more medical interventions including costly care in a neonatal intensive care
unit (Riskin-Mashiah, Younes, Damti & Auslender, 2009) and separation of infants from
their mothers in the critical first hours of life. Long-term effects exist beyond the
newborn period and may contribute to the increasing rates of obesity and diabetes
(Ryan, 2013).
The most commonly known condition which causes hyperglycemia in pregnancy
is gestational diabetes mellitus which affects 2-13% of all pregnancies, depending upon
the population group studied (Poel et al., 2012). Gestational diabetes mellitus is one of
the most common complications in pregnancy (Macones, 2012; Poel et al., 2012) and the
prevalence is rising worldwide (Lehnen, Zechner & Haaf, 2013). In addition, gestational
3

diabetes markedly increases the risk of a woman developing type 2 diabetes in later life
(Makgoba et al., 2011).
Gestational diabetes mellitus has been extensively researched in the professional
literature for many years. Less has been written about blood glucose levels in the upper
limit of normal but not over the threshold for a diagnosis of GDM. Many healthy women
fit into this category during pregnancy. Since there is a paucity of scientific literature on
hyperglycemia during pregnancy for healthy women, some of the research on GDM will
be considered as proxy to hyperglycemia in this study to gain insight into the effects of
hyperglycemia in pregnancy.
One major study to fill the knowledge gap on the link between mild, maternal
hyperglycemia and pregnancy outcomes was the Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) study which involved 15 centers in 9 countries and over 25,000
pregnant women (Coustan, Lowe, Metzger, & Dyer, 2010; Leary, Pettitt & Javanovic,
2010). The HAPO study revealed that maternal hyperglycemia at levels less than
required for a diagnosis of GDM do pose a risk for adverse outcomes for the offspring
(Coustan et al., 2010; The HAPO Study Cooperative Research Group, 2008). The HAPO
study was powered to detect the primary outcomes of neonatal hypoglycemia,
hyperinsulinemia and macrosomia in the infant, and primary cesarean birth in the
mothers (Coustan et al., 2010). The secondary outcomes of the HAPO study included
birth at <37 weeks gestation, birth injury (such as shoulder dystocia), hyperbilirubinemia,
and need for neonatal intensive care (Coustan et al., 2010; HAPO Study Cooperative
Research Group, 2002). These findings demonstrate the harm which can result from
maternal hyperglycemia during pregnancy supporting the need for prevention strategies.
4

Brief Overview of Vitamin D Metabolism
Vitamin D comes from two sources which are identified as vitamin D2
(ergocalciferol) or vitamin D3 (cholecaliciferol). Vitamin D is unique in that it is
considered both a vitamin and a pro-hormone with a vitamin D receptor found in nearly
every cell in the human body (Holick, 2005; Lips, 2006; McCullough, 2007; Pittas &
Dawson-Hughes, 2010). Vitamin D is synthesized from direct sunlight on exposed skin
or obtained from supplements, fortified foods, or one of the few foods which naturally
contain vitamin D (Thorne-Lyman & Fawzi, 2012; Specker, 2004). Synthesis of vitamin
D in the skin can be affected by latitude, season of the year, cloud cover, pollution, age,
body mass index (BMI), the amount of melanin in the skin, ethnicity, genetics, renal
function and liver function (Collins-Fulea, Klima & Wegienka, 2012; Holmes, Barnes,
Alexander, McFaul, & Wallace, 2009; Prentice, 2008; Wicherts et al., 2011).
Hypovitaminosis-D
Vitamin D deficiency is a problem worldwide (Ginde, Sullivan, Mansbach &
Camargo, 2010; Hanley & Davison, 2005). Hypovitaminosis-D affects nearly 41.6% of
the adults in the United States according to the National Health and Nutrition
Examination Survey (NHANES) report (Forrest & Stuhledreher, 2011).
Hypovitaminosis-D is often a problem for women, especially those who live in Northern
latitudes, have darkly pigmented skin, or those whose clothing prohibits direct sunlight
on exposed skin (Holick & Chen, 2008). Maghbooli, Hossein-nezhad, Karimi, Shafaei
and Larijani (2008) reported that hypovitaminosis-D was found in 70.6% of the pregnant
women in their research in Iran. In Oakland, California, 54.4% of pregnant women were
found to have hypovitaminosis-D (Dror, King, Durand, & Allen, 2011). In the United
5

States, 69% of pregnant women were found to have hypovitaminosis-D from a secondary
analysis of the National Health and Nutrition Examination Survey (NHANES) from 2001
– 2006. The NHANES study collected data on women of childbearing age which ranged
from 13-44 years so this data set included younger pregnant women (Ginde, Sullivan,
Mansbach & Camargo, 2010). Ginde et al. (2010) reported that younger pregnant women
were more frequently nonwhite (57%), lower socioeconomic status, and not using any
vitamin D supplements and all of these factors increased their risk of hypovitaminosis-D
in pregnancy. They further reported the novel finding of similar rates of
hypovitaminosis-D in Hispanic and non-Hispanic blacks which they concluded was likely
to decreased synthesis of vitamin D in the skin due to the levels of melanin. Wagner et
al. (2015) found the mean serum calcidiol level in early pregnancy was 58 nmol/L (5 –
185 nmol/L) in a sample of over 400 women.
Calcidiol in Pregnant Women
Calcidiol levels are unlikely to change in pregnancy unless there is an increase in
synthesis (cholecalciferol from the sun; D3) or intake from plants and absorbed through
the gut (ergocalciferol, D2), or intake from supplements (either D2 or D3) (Gabbe et al.,
2012, p. 59). The active metabolite of vitamin D, calcitriol, progressively increases
during pregnancy (Barrett & McElduff, 2010; Hollis, Johnson, Hulsey, Ebeling, &
Wagner, 2011; Holmes et al., 2009). Holmes et al. (2009) suggest that there is an
increased demand for vitamin D during pregnancy to support these higher levels of
calcitriol. Hollis et al. (2011) found that women with higher intake of oral vitamin D
supplements had higher calcitriol levels as pregnancy progressed when compared with
women who had lower intake of vitamin D supplements.
6

Calcidiol and Glucose Metabolism
Insufficient vitamin D may be associated with insulin resistance with the resulting
hyperglycemia. Serum calcidiol is the usual measure for vitamin D and low levels may
be a risk factor for impaired glucose metabolism leading to hyperglycemia (Forouhi et
al., 2008; Wang et al., 2012). Several researcher have reported an association between
calcidiol levels and glucose metabolism (Chiu, Chu, Go & Saad, 2004; Forouhi et al.,
2012; Moreira & Hamadeh, 2010; Holick, 2005; Pittas & Dawson-Hughes, 2010;
Palomer, Gonzalez-Clemente, Blanco-Vaca & Mauricio, 2008; Song & Manson, 2010).
McLeod et al. (2011) found an association between serum calcidiol levels and pancreatic
β-cell function linking vitamin D with an effect on insulin production and glucose
metabolism. Kayaniyil et al. (2011) reported higher calcidiol levels independently
predict improved pancreatic β-cell function. These studies illustrate the emerging
evidence on the positive influence of vitamin D on glucose metabolism.
Serum Calcidiol and Glucose Metabolism in Pregnancy
Vitamin D may have the potential to positively influence glucose metabolism
during pregnancy. A limited number of researchers have studied the relationship
between serum calcidiol levels in the first trimester and impaired glucose metabolism in
pregnancy (Baker et al., 2012; Fernandez-Alfonso et al., 2012; Makgoba et al., 2011;
Tomedi et al., 2013). Others have examined the relationship between serum vitamin D
levels in the second trimester and the blood glucose levels in mid-pregnancy (Burris et
al., 2012; Clifton–Bligh et al., 2008; Maghbooli et al., 2008; Parlea et al., 2012;
Soheilykhah et al., 2010; Zhang et al., 2008). Two studies were found which looked at
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serum vitamin D level in the third trimester and glucose metabolism in pregnancy
(Farrant et al., 2009; Lau et al., 2011).
More specifically, some researchers have found an inverse relationship between
serum calcidiol levels and maternal blood glucose levels in pregnancy. Burris et al.
(2012) examined second trimester calcidiol and blood sugar levels when using a one-hour
glucose screening test. Their results indicated that hypovitaminosis-D may increase the
risk of impaired glucose metabolism. A few observational studies indicated a significant
difference in serum calcidiol in women with impaired glucose metabolism versus normal
glucose tolerance (Clifton-Bligh, 2008; Maghbooli, 2007; Soheilykhah, 2010; Zhang,
2008) and reported a correlation between maternal vitamin D status and impaired glucose
metabolism. Hypovitaminosis-D has been associated with impaired glucose metabolism
in both pregnant and non-pregnant humans (Alzaim & Wood, 2013). Pregnant women
with hypovitaminosis-D may be at increased risk for hyperglycemia (Shin, Choi,
Longtine & Nelson, 2010) but it still is not clear if this is a causal relationship (Poel et al.,
2012). Therefore, a need exists to further explore the association between vitamin D and
glucose metabolism.
Purpose Statement
The purpose of this study was to determine the relationship between calcidiol
levels collected in early, mid, and late pregnancy and blood glucose levels in mid
pregnancy in a sample of women in an upper Midwestern region of the United States. A
quantitative, correlational design was used in a secondary analysis to ask new questions
of an existing data set. According to Pridjian and Benjamin, (2010), hyperglycemia
during pregnancy is associated with adverse outcomes for both the mother and baby. It is
8

known that calcidiol influences glucose metabolism in the non-pregnant population
(Alfonso et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al., 2013) and this
study investigated the influence of calcidiol on glucose metabolism in the pregnant
population. The significance of this relationship is that it may inform an understanding
of the effect of calcidiol on glucose metabolism in pregnancy. By identifying the
correlation between calcidiol and glucose levels, there is the potential to mitigate
hyperglycemia in pregnancy and improve the health of infants and mothers.
Research Hypothesis
The working hypothesis for this study was that there is an inverse relationship
between calcidiol during pregnancy and mid pregnancy blood glucose levels.
Research Questions
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and
the blood glucose (BG) level at 24-28 weeks gestation when controlling for the known
confounding variables of age and pre-pregnancy body mass index (BMI)?
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the
BG level at 24-28 weeks gestation when controlling for the known confounding variables
of age and BMI?
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and
the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI?
Problem Statement
Although studies are emerging which support an association between vitamin D
levels and impaired glucose metabolism (Alzaim & Wood, 2013), there are inconsistent
9

findings on the effects of vitamin D and maternal glucose levels during pregnancy. It is
known that many women have hypovitaminosis-D during pregnancy (Aslam, Masood,
Sattar, & Qudsia, 2012) and that some women develop impaired glucose metabolism in
pregnancy (Davenport, Campbell, & Mottola, 2010; Evenson, 2012; Hunt & Schuller,
2007; Veeraswamy, Vijayam, Gupta, & Kapur, 2012). A need exists to learn more about
the effect of vitamin D on maternal glucose levels in pregnant women (Joergensen,
Lamont & Torloni, 2014; Senti, Thiele, & Anderson, 2013). Addressing this gap in
knowledge may contribute to strategies which could improve glucose metabolism in
pregnancy.
Theoretical Framework
The Neuman Systems Model (NSM) provides a unifying focus for a wide range
of health concerns by using open systems-based approach (Neuman, 2011). The Neuman
model is concerned with the patient’s reaction and response to environmental stressors,
both external and internal (Gigliotti, 2003). According to the NSM, clients who need
nursing care are people dealing with stressors or anticipating stressors (such as
physiologic variables) in their environment. The model defines universal, basic survival
factors which include genetic factors and the innate strengths and weaknesses within the
client system (Meleis, 2012). According to Neuman and Reed (2007), the NSM is
comprised of several key components that provide the mechanism for attaining optimal
wellness. These components include five variables within the client’s system
(physiological, psychological, developmental, sociocultural, and spiritual), the interaction
with the environment (internal, external, or created), and three prevention levels. The
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model also includes lines of resistance and lines of defense (flexible and normal) as part
of the interaction (Gigliotti, 2003).
The normal line of defense is the inner boundary of the client system, defines its
integrity and stability, and is used to measure variance from wellness (Neuman, 2005).
The flexible line of defense is the outer boundary of the client system and functions as a
buffer by preventing stressor invasion of the client’s system (Neuman, 2005). The
protective internal and external mechanisms which work to stabilize the client system and
maintain wellness are the lines of resistance and support the basic structure of the client,
such as the immune system (Neuman, 2005). The metabolic demands of pregnancy are
an internal, physiological stressor which can cause imbalance from insulin resistance and
hyperglycemia which results in impaired glucose metabolism. In Neuman’s model, the
goal of nursing is to prevent or correct instability (Meleis, 2010). Using the NSM,
interventions by the nurse include helping the individual patient identify barriers to
change and helping her discover ways to improve her diet and activity (external
environment) to balance maintain normal blood glucose levels (internal environment).
This will reduce the physiological stressors in her internal environment, restore health,
and improve the outcome of the pregnancy for both her and her baby.
The diagnosis of impaired glucose metabolism creates a psychological stressor.
The woman may feel overwhelmed and fearful for herself and her baby. Persson,
Winkvist and Mogren (2010) found that women with this condition expressed a change in
self-image and a loss of normalcy. Using the NSM, the nurse can enter into a bonding
partnership by providing individualized attention for the client, compassionate care,
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specific education, and encouragement (Neuman & Reed, 2007). Such a partnership can
reduce the psychological stressors to restore well-being.
Significance of Study
Since hyperglycemia during pregnancy results in long-term health consequences
for both mother and baby (Pridjian & Benjamin, 2010), there is a need for interventions
which can improve glucose metabolism during pregnancy. Hypovitaminosis-D has been
associated with impaired glucose metabolism in the non-pregnant population (Parlea et
al., 2011). Since hypovitaminosis-D occurs in 70.6% of pregnancies (Maghbooli et al.,
2008), a correlation between hypovitaminosis-D in pregnancy and maternal
hyperglycemia would be noteworthy and may support vitamin D supplementation as an
intervention to improve glucose metabolism in pregnancy (Tomedi, Simhan, & Bodnar,
2013). The goal of this research was to contribute to the science by identifying if there is
an inverse relationship between maternal calcidiol status and blood glucose levels at midpregnancy. If such a relationship exists, the next step would be to determine therapeutic
levels for maternal serum vitamin D for optimal glucose homeostasis. Appropriate
supplementation could be a cost effective strategy for reducing hyperglycemia in
pregnancy, thus enhancing the health of mothers and their children.
Assumptions
There were several assumptions in this study. It was assumed that the participants
all volunteered for the study, met the selection criteria, were truthful in their responses,
and followed instructions correctly. It was also assumed that the participants were
relatively healthy when the testing was done and were not taking any medications or
experiencing other conditions which could affect results. The sample was considered to
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be an accurate reflection of the population studied (pregnant, nulliparous women in the
upper Midwest). The last assumption was that all laboratory testing techniques were
done properly with reliable and accurate results.
Summary of Key Points
1. Vitamin D deficiency is a problem worldwide and affects over 40% of the
adults in the United States alone.
2. In the second half of pregnancy, women have increased insulin resistance.
Insulin resistance is part of the complex process from placental hormones
which reprograms the maternal physiology to meet the needs of the fetus.
3. Impaired glucose metabolism is a complication of pregnancy with significant
short-term and long-term consequences for both women and their offspring.
4. Impaired glucose metabolism in pregnancy includes insulin resistance and
impaired pancreatic β-cell function which affects insulin production.
5. Vitamin D has been shown to influence glucose metabolism in the nonpregnant population.
6. Both hypovitaminosis-D and impaired glucose metabolism are common
conditions, especially for women in the Northern Plains of the United States.
7. Hypovitaminosis-D occurs during pregnancy for certain groups at risk.
8. Hypovitaminosis-D may be associated with elevated blood glucose levels in
pregnancy.
9. Vitamin D supplementation during pregnancy may improve glucose
metabolism.
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10. A gap in knowledge exists regarding the relationship between the serum
vitamin D levels in pregnancy and blood glucose levels at 24-28 weeks of
gestation.
11. Finding a cost effective, easily implemented intervention to improved glucose
metabolism in pregnancy would contribute to both science and clinical
practice.
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CHAPTER II
REVIEW OF LITERATURE
Introduction
This chapter contains a review of the literature related to the relationship between
vitamin D levels at different times in pregnancy and the blood glucose level in midpregnancy. In the non-pregnant population, there is growing evidence that vitamin D is
an important regulator of blood sugar metabolism and influences increased insulin
secretion (Forouhi et al., 2008; Hirani, 2011) which has generated interest on the
influence of maternal vitamin D status on blood glucose metabolism in pregnancy. The
topics covered in this review include metabolic changes in pregnancy related to glucose
metabolism, the effects of hyperglycemia during pregnancy on both the woman and her
offspring, an overview of vitamin D including the effect on glucose metabolism, and the
influence of vitamin D on glucose metabolism in pregnancy. The review of literature
provided the foundation for the research questions for this study.
Definitions
The following definitions of terms used in the current study are written below to
provide clarity:
Active vitamin D: 1,25(OH)2D; the hormonal form of vitamin D; also known as
calcitriol. In this paper, the term calciTRiol will be used.
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Blood glucose level (BG): amount of glucose in the blood measured in mg/dl. In
this study, the BG was obtained at 24-28 weeks gestation after ingestion of a 50 gram
glucose beverage at a GDM screening. Sometimes commonly called blood sugar.
Elevated BG at GDM screening: >140 mg/dl one hour after ingestion of 50 gram
glucose beverage at 24-28 weeks of gestation (Hartling et al., 2012; Hollander, Paarlberg
& Huisjes, 2007)
Gestational diabetes mellitus (GDM): carbohydrate intolerance of variable
severity with onset or first recognition during pregnancy. A blood glucose level > 140
mg/dl at the GDM screening test or a diagnosis of GDM in the medical record
abstraction.
Glucose intolerance: hyperglycemia secondary to insulin resistance.
Hypovitaminosis-D: insufficient or deficient vitamin D level indicated by a blood
serum calcidiol which is less than adequate for this population. In this paper, vitamin D
is being studied for a non-skeletal influence and therefore level has been set at < 75
nmol/L. See the review of the literature for further details.
Hyperglycemia: an abnormally high concentration of glucose in the blood. For
the purposes of this paper, this means a blood glucose level > 140 mg/dl at the GDM
screening test
Insulin resistance: physiologic condition in which insulin is produced by the
pancreas but the cells fail to respond adequately which results in the need for the
pancreas to produce higher amounts of insulin to maintain glucose homeostasis
IU: International Unit
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Serum vitamin D: 25(OH)D level in the blood serum, also known as calcidiol or
25-hydroxyvitamin D. It is the stored form of vitamin D that circulates in the body.
Serum calcidiol is used to measure vitamin D levels. See methods for data collection
information. In this paper, the term calciDiol will be used.
Vitamin D: generic descriptor for all steroids exhibiting the biologic activity of
ergocalciferol or cholecalciferol. They promote the proper use of calcium and
phosphorus, thereby favoring proper bone and tooth formation. The physiological
processes which begins with vitamin D intake from synthesis or consumption and
becomes the active, hormonal form is very complex and is discussed in the review of
literature.
Vitamin D2: ergocalciferol; the activated ergosterol, the vitamin D of plant origin;
sterol occurring naturally in fungi and some fish oils or synthesized from ergosterol; it
arises from ultraviolet irradiation of ergosterol, and similar to cholecalciferol in activity
and metabolism. It is added to foods such as milk as a dietary source of vitamin D or
used as a supplement.
Vitamin D3: cholecalciferol; vitamin D of animal origin found in the skin of
animals exposed to sunlight; can also be manufactured as a supplement
VitD-early: calcidiol level drawn at 10-14 weeks gestation; also VitD.early
VitD-mid: calcidiol level drawn at 22-26 weeks gestation; also VitD.mid
VitD-late: calcidiol level drawn at 32-26 weeks gestation; also VitD.early
Weeks of gestation, weeks gestation: designation of time frame in pregnancy
measured in completed weeks
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Adaptations to Glucose Metabolism in Pregnancy
Pregnancy is a time of significant alterations and increasing metabolic demands
for the woman (Torgersen & Curran, 2006) including changes in glucose metabolism
(Cunningham et al., 2013; Evensen, 2012). In pregnancy, there are progressive changes
in glucose metabolism which result in a decrease in fasting blood glucose (Gabbe et al.,
2012, p. 889), sustained postprandial elevation, and hyperinsulinemia (Cunningham et al.,
2013). In the first trimester, this is likely due to the increase in plasma volume (Gabbe et
al., 2012, p. 889) which begins at six weeks and continues through the second trimester
(Torgersen & Curran, 2006) while in later pregnancy, this is most likely as a result of the
glucose needs of the fetus and placenta.
The placenta obtains glucose primarily through facilitated diffusion and the main
glucose transporter in the placenta is GLUT1 (Brett, Ferraro, Holick & Adamo, 2015;
Brett, Ferraro, Yockell-Lelievre, Gruslin, and Adamo, 2014; Day, Cleal, Lofthouse,
Hanson & Lewis, 2013). This results in non-insulin mediated glucose utilization by both
the fetus and the placenta which gradually increases with advancing gestation, which
further contributes to the changing glucose metabolism in pregnancy. There is an
increased potential for the transport of glucose to the fetus correlated to maternal sugar
intake (Brett et al., 2015). Simultaneously as the gestation advances, women develop
decreasing peripheral insulin sensitivity, a gradual decrease in fasting blood glucose
levels, and a progressive increase in the postprandial blood sugar levels (Gabbe et al.,
2012, p. 888-890). The availability of nutrients in the maternal circulation influences
nutrient transport to the fetus by the placenta (Brett et al., 2015). The placenta is
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considered to be a dynamic, responsive organ in the transport of glucose and other
nutrients to the fetus.

Figure 1. Glucose transport in placenta to fetus.
Changing Insulin Metabolism
Early pregnancy is characterized by alterations in maternal metabolism to provide
adequate nutrition to the placenta and the fetus. These metabolic changes are attributed
to pregnancy-related hormones including human placental lactogen, estrogen,
progesterone, prolactin, and cortisol (Evenson, 2012; Maghbooli et al., 2008). Glucose
metabolism is changed by an increase in insulin resistance and reduced uptake of glucose
by maternal tissues which results in higher postprandial blood glucose levels (Maghbooli
et al., 2008). Simultaneously, the placenta utilizes glucose which then results in lower
fasting blood glucose levels (Gabbay-Benziv & Baschat, 2015). As the pregnancy
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progresses the insulin resistance increases to facilitate glucose delivery to the fetus
(Evensen, 2012).
Factors Contributing Insulin Resistance in Pregnancy
Normally, this state of increased insulin resistance in the second half of pregnancy
is similar to the underlying pathophysiology of type 2 diabetes (Evensen, 2012; Jelsma et
al., 2013). In both conditions, the increasing insulin resistance along with an inadequate
response of the β-cells to produce the amount of insulin needed leads to hyperglycemia
(Gabbe et al., 2012, p. 892). Although not yet fully understood, insulin receptors found
in the placenta undergo developmental changes as the pregnancy progresses which
strongly suggest a shift from maternal control to fetal control of insulin dependent
functions (Desoye & Hauguel-de Mouzon, 2007). In the microvillus trees of the
placenta, there is diffusion of glucose from the higher concentration in the maternal blood
supply to the lower concentration on the fetal side of the placenta. The glucose supplied
to the developing fetus is dependent upon the concentration gradient between the mother
and baby. The main glucose transporter in this process is GLUT1 which provides a
binding site at the basal membrane and faster, facilitated diffusion. The placenta also
utilizes a considerable amount of glucose which buffers the glucose fluctuations to the
fetus (Barta & Drugan, 2010).
Maternal Hyperglycemia in Pregnancy
Hyperglycemia occurs in pregnancy when the body is unable to respond to the
physiologic changes by increasing insulin production to meet the changes in glucose
metabolism (Coustan, 2013). Emerging research demonstrates that maternal
hyperglycemia is clinically important, even when less severe than the level associated
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with a diagnosis of gestational diabetes mellitus (The HAPO Study Cooperative Research
Group, 2008). Glucose metabolism is on a continuum (Salzer, Tenenbaum-Gavish &
Hod, 2015) with a linear association between maternal blood glucose levels in pregnancy
and unfavorable perinatal outcomes (Tieu, McPhee, Crowther & Middleton, 2014). A
fetus is more sensitive to hyperglycemia than to hypoglycemia when it comes to
well-being (Evensen, 2012). Studies such as the HAPO study demonstrate that adverse
outcomes for mother and baby can be a result of hyperglycemia in pregnancy (Coustan
Lowe, Metzger, & Dyer, 2010). However, the threshold for maternal blood glucose
levels which predicts adverse perinatal outcomes has not yet been found (Tieu, McPhee,
Crowther, & Middleton, 2014).
The HAPO study examined any association between blood glucose levels and
adverse pregnancy outcomes (Coustan et al., 2010). Over 25,000 women were involved
in the study and various research teams analyzed the data. Fasting blood sugar (FBS)
levels and/or oral glucose tolerance test (OGTT) results were used and the study was
powered for the primary outcomes of macrosomia, neonatal hypoglycemia, cesarean
delivery, and hyperinsulinemia (Coustan et al., 2010). The secondary outcomes in the
HAPO study included shoulder dystocia, preterm birth, birth injury, neonatal intensive
care admission, pre-eclampsia, and hyperbilirubinemia (Coustan et al., 2008). Both
obesity and gestational diabetes mellitus pose a greater risk for adverse outcomes in
pregnancy with a combination of both leading to even greater risk for these unfavorable
consequences (Catalano et al., 2012).
Maternal blood glucose was considered a continuous variable for the analysis
(Coustan et al., 2010). Maternal hyperglycemia at levels less severe than GDM causes
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fetal hyperinsulinemia and fetal overgrowth (The HAPO Study, 2009). The adverse
effects of maternal hyperglycemia on the infant can result in the need for more medical
interventions at birth including costly admissions to the neonatal intensive care unit
(Landon et al., 2012; Desoye & Hauguel-de Mouzon, 2007; Vambergue & Fajardy,
2011). The HAPO Study (2009) concluded that there is a need to look at treating
hyperglycemia in pregnancy, considering the findings of adverse outcomes.
When the fetus is exposed to ongoing hyperglycemia in utero, there is an
increased risk for the adult onset of disease (Lapillone, 2009; Lehnen et al., 2013; Tieu et
al., 2014; Veeraswarmy et al., 2012). Prolonged maternal hyperglycemia during
pregnancy can lead to health problems in later life for the offspring including childhood
obesity, development of metabolic syndrome, and type 2 diabetes in young adulthood
(Tieu et al., 2014; Veeraswamy, Vijayan, Guptz, & Kapur, 2012). Fetal overnutrition at
periods critical in fetal development (Javaid et al., 2006) can lead to metabolic conditions
such as obesity, glucose intolerance, or type 2 diabetes. These studies demonstrates how
such conditions can originate from the effects of the intrauterine environment on the
developing fetus (Hunt & Schuller, 2007; Lehnen et al., 2013; Veeraswarmy et al., 2012).
The known physiologic changes in pregnancy which can results in prolonged
hyperglycemia have resulted in routine screening protocols to diagnose gestational
diabetes mellitus (GDM) (Tieu et al., 2014). The protocols were implemented because
GDM can occur among pregnant women traditionally considered to be low risk for
complications (Holmes et al., 2009; Lehnen et al., 2013; Macones, 2012; Poel et al.,
2012). Gestational diabetes mellitus (GDM) is briefly defined as carbohydrate
intolerance that is first recognized during pregnancy (Asemi, Hashemi, Karamali,
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Samimi, & Esmaillzadeh, 2013). Left uncontrolled, GDM can result in hyperglycemia
during pregnancy with the resulting adverse effects. Infants of women with GDM have
increased perinatal morbidity including macrosomia, hypoglycemia, respiratory distress
syndrome, and jaundice (Coustan, 2013).
Vitamin D Metabolism
Vitamin D is recognized today as a prohormone (Institute of Medicine, 2011) and
is a unique nutrient because it is obtained through cutaneous synthesis from ultraviolet
rays from direct sunlight (from UVB radiation at 290-320 nm) on exposed skin (Brannon
& Picciano, 2011) and can also be obtained through certain foods or dietary supplements
(Specker, 2004; Tomedi, Simhan, & Bodnar, 2013). Vitamin D2 (ergocalciferol) is
naturally found in a few foods or is manmade (IOM, 2011; Specker, 2004). Vitamin D3
(cholecalciferol) is produced in human skin from 7-dehydrocholesterol (7-DHC) or
ingested through animal based foods (IOM, 2011). Both forms, D2 and D3, are
commercially manufactured for supplements (IOM, 2011).
Both forms of vitamin D (D2 and D3) are biologically inactive and must undergo
two hydroxylations before becoming biologically active (Brannon & Picciano, 2011;
Holick & Chen, 2008). The first hydroxylation occurs in the liver where an enzyme, 25hydroxylase (CYP2R1), converts vitamin D into 25-hydroxyvitamin D which is also
referred to as 25(OH)D or calcidiol (Brannon & Picciano, 2011; Holick & Chen, 2008;
IOM, 2011). Calcidiol is the major form of vitamin D in the circulation and is bound to a
carrier protein, vitamin D binding protein (known as VDP) in the plasma (IOM, 2011).
Calcidiol has a half-life of 15 days (Jones, 2008) and is the best indicator of serum
vitamin D status (Holick & Chen, 2008; Olmos-Ortiz, Durand-Carbajal, & Diaz, 2015)
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because it reflects the cumulative effect of sunlight, diet, and supplements in the
circulation (Kovacs, 2013). Although calcidiol has a sufficient half-life to most
accurately reflect the vitamin D from all sources (Brannon, 2012), it does not accurately
reflect the stores within the body tissues (National Institutes of Health, n.d.).
Calcidiol is changed into calcitriol (1,25(OH)2D) through the second
hydroxylation in the maternal kidneys and, in lesser amounts by the fetal kidneys, the
placenta, the decidua, and diverse tissues (Barrett & McElduff, 2010; Kovacs, 2013). An
enzyme in the kidneys, 1α-hydroxylase (CYP27B1), converts the calcidiol into the
physiologically active form, 1,25 dihydroxyvitamin D, which is also referred to as
1,25(OH)2D or calcitriol (Holick & Chen, 2008; IOM, 2011). Calcitriol synthesis in the
kidney is tightly controlled with up-regulation by the parathyroid hormone and downregulation by fibroblast-like growth factor. Some extra-renal tissues contain 1αhydroxylase, but it is yet unknown how this contributes to calcitriol production (IOM,
2011). Calcitriol acts through the vitamin D receptors (VDR) to produce the favorable
biological effects (Lapillonne, 2009). Calcitriol which has a half-life of 15 hours (Jones,
2008) yet levels of calcitriol typically do not decrease until there is severe vitamin D
deficiency (NIH, n.d.). Calcitriol has a significant physiological influence on essentially
every tissue and cell in the human body (Holick, 2005; Lips, 2006; McCullough, 2007;
Pittas & Dawson-Hughes, 2010) and may even have a protective effect against many
diseases (Lapillone, 2009).
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Figure 2. Vitamin D metabolism.
Hypovitaminosis-D
Concerns exist about the high prevalence of hypovitaminosis-D in pregnancy
(Bodnar et al., 2007; Brannon & Picciano, 2011) which exists in almost every population
studied (Dror, King, Durand, & Allen, 2011). Today, hypovitaminosis D can be
attributed to lifestyle changes which result in less sunlight exposure on bare skin from the
use of sunscreen, fewer hours spent outside, and clothing choices due to culture or
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climate (Dawodu & Akinbi, 2013; Wagner et al., 2013; Wang et al., 2013). The reduced
amount and seasonal nature of sunlight exposure, smoking, and obesity have all been
associated decreased vitamin D levels (Andersen et al., 2013; Evensen, 2012). Vitamin
D synthesis from direct sunlight is reduced as melanin increases in the skin or due to
changes in UV radiation from sunlight when people live at higher latitudes (Holick &
Chen, 2008; Schroth, Lavelle, & Moffat, 2005). The individual’s metabolism of vitamin
D can be influenced by factors which include renal function, liver function, ethnicity, and
genetic effects (Collins-Fulea et al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts
et al., 2011).
Prevalence of Hypovitaminosis D
Vitamin D deficiency is a problem worldwide and may affect as much as 42% of
the adults in the United States (Forrest & Stuhledreher, 2011; Ginde, Sullivan, Mansbach,
& Camargo, 2010; Hanley & Davison, 2005; Holick, 2008; Vieth, 2006). Some
researchers have described hypovitaminosis D as reaching pandemic levels because it is
prevalent in Asia, China, the Scandinavian countries, the United Kingdom, Canada, the
northern United States, and in African Americans (Holick & Chen, 2008; Glerup et al.,
2000; Hanley & Davison, 2005; Wang et al., 2012). The prevalence of hypovitaminosisD is approximately 5-29% of pregnant women in the United States (Brannon & Picciano,
2011).
The Institute of Medicine (IOM) developed the dietary reference intakes (DRI)
through a joint effort between the United States and Canadian governments (Aloia,
2011). The DRI of vitamin D was recently increased from 400 IU to 600 IU daily for
adults, including pregnant women (Aloia, 2011). Many researchers believe this is still
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not adequate and argue that the DRI should be 800-2000 IU (Ginde et al., 2010; Hanley
& Davison, 2005; Heaney, 2005). The most effective method to achieve an increase in
vitamin D is through dietary supplements (Hanley & Davison, 2005; Heaney, 2005;
Thorne-Lyman & Fawzi, 2012). The IOM recommendations state that vitamin D toxicity
is unlikely to occur until doses exceed 10,000 IU/day (IOM, 2011). However, vitamin D
intake and serum vitamin D levels do not have a linear relationship (IOM, 2011) so the
best way to determine vitamin D status is through a serum calcidiol level (Holick &
Chen, 2008; Olmos-Ortiz et al., 2015).
Vitamin D in Pregnant Women
Unless there is an increase in intake of vitamin D from diet, supplements, or from
synthesis in the skin, serum calcidiol levels don’t change during pregnancy (Gabbe et al.,
2012, p. 59). During pregnancy, calcitriol progressively increases by 50-100% in the
second trimester and to twice the pre-pregnancy level in the third trimester, most likely
due to production by the increasing placental mass (Cho, Hong, Oh, & Kim, 2013). This
change occurs from an increase in production of calcitriol from calcidiol by the maternal
kidneys as well as conversion of calcidiol into calcitriol by the placenta, the decidua and
the fetal kidneys (Barrett & McElduff, 2010; Kovacs, 2013). The increase in maternal
calcitriol starts in early pregnancy but the increase in free calcitriol does not occur until
late pregnancy. This occurs because the maternal kidneys upregulate the expression of
the enzyme, CYP27B1, which increases the production of calcitriol. The fetal kidneys,
the placenta, and the maternal decidua are also sources of CYP27B1 expression but only
results in a small amount of calcitriol. Their contribution is not enough to account the
increase of calcitriol in maternal circulation in pregnancy (Kovacs, 2013).
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Hypovitaminosis-D in Healthy Pregnant Women
Hypovitaminosis-D was detected in women of childbearing age who are
considered healthy and at low risk for pregnancy complications (Holmes et al., 2009).
Although vitamin D levels were significantly lower in the pregnant women in their study,
Holmes et al. (2009) reported hypovitaminosis-D in the non-pregnant women from the
control group in their study demonstrating that hypovitaminosis-D is prevalent in all
women who are of childbearing age. Specific groups of pregnant women such as those
who are veiled or have deeply pigmented skin have a high prevalence of
hypovitaminosis-D (Bodnar et al., 2007; Dawodu & Akinbi, 2013; Marwaha et al., 2011;
Wagner et al., 2013; Wang et al., 2013).
The Endocrine Society and the Institute of Medicine (IOM) have differing
recommendations on the amount of vitamin D supplementation required in pregnancy.
The IOM recommends 600 IU/day of vitamin D for all adults with no change for women
during pregnancy (IOM, 2011). The Endocrine Society recommends 600 IU of vitamin D
daily for pregnant women between 14-18 years of age and 1500-2000 IU daily for
pregnant women ages 19-50 years of age (Holick et al., 2011). If needed, The Endocrine
Society recommends supplementations of 1,500-2,000 IU of vitamin D daily to reach a
target level of serum calcidiol of 75 nmol/mL (Hollis et al., 2011). However, Kovacs
(2013) reports that women do not need more vitamin D during pregnancy as compared to
the non-pregnant state because maternal calcitriol normally increases in pregnancy due to
increased expression of CYP27B1 in the maternal kidneys. Kovacs (2013) states that
there is inconsistent data for any non-skeletal benefits from vitamin D and does not
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recommend additional vitamin D during pregnancy until clinical trials prove there is a
need.
Hypovitaminosis-D is prevalent in many women during pregnancy (Aslam et al.,
2012; Hollis et al., 2011; Maghbooli et al., 2008) underscoring the importance of
investigating the effect of vitamin D on health outcomes related to this population
(Barrett & McElduff, 2010; Ginde et al., 2010; Holmes et al., 2009; Mulligan, Felton,
Riek, & Bernal-Mizrachi, 2010). Universal screening is not recommended at this time,
but targeted screening may be indicated for pregnant women in some at-risk groups
(Collins-Fulea et al., 2012). Serum levels of calcidiol increase in proportion to intake
through both sunlight exposure and oral intake from supplements or food (IOM, 2011).
The dose-response varies in individuals based on the degree and duration of
supplementation and the baseline calcidiol levels (IOM, 2011).
Hypovitaminosis-D and Glucose Metabolism
The National Health and Nutrition Examination Survey (HANES) showed an
inverse association between diabetic risk and serum calcidiol for some ethnic groups, but
not for all (Scragg, Sowers, & Bell, 2004). There is evidence that vitamin D has an effect
on glucose metabolism (Chiu et al., 2004; Forouhi et al., 2012; Moreira & Hamadeh,
2010; Holick, 2005; Pittas & Dawson-Hughes, 2010; Palomer et al., 2008) but the
physiological reason is not fully understood. It is unknown if vitamin D affects insulin
sensitivity, β-cell function in the pancreas, or a combination of these (Clifton-Bligh et al.,
2008). Several researchers have shown that vitamin D affects β-cell function in the
pancreas, insulin secretion and insulin resistance which subsequently affects blood
glucose metabolism (Alfonso et al., 2009; Kayaniyil et al., 2011; Zhao, Ford & Li, 2010).
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Others have reported an inverse association between hypovitaminosis-D and insulin
resistance, plasma glucose levels, and diabetes (Chiu et al., 2004; Ford, Ajani, McGuire
& Lui, 2005; Forouhi et al., 2008; George, Person & Witham, 2012; Heaney, 2005;
Kayaniyil et al., 2010; Moreira & Hamadeh, 2010; Patra et al., 2012; Pittas et al., 2010).
McLeod et al. (2012) reported that vitamin D may affect glucose metabolism through
influence of β-cell function. In summary, there is evidence that vitamin D influences
glucose metabolism through insulin production or sensitivity, though the precise details
have yet to be determined.
Insulin resistance contributes to hyperglycemia and impaired glucose tolerance
(IGT) which is then linked to the development of diabetes mellitus (Muscogiuri et al.,
2011; Song & Mason, 2010). A study in healthy young adults with normal glucose
metabolism demonstrated an association between hypovitaminosis-D and decreased
insulin secretion which was normalized after vitamin D supplementation (Jorde &
Figenschau, 2009). Another study demonstrated that vitamin D3 supplementation
improved postprandial sensitivity in a targeted group (Nagpal, Pande, & Bharita, 2009).
Some researchers have suggested that higher levels of vitamin D might have a protective
effect against development of both type 2 and type 1 diabetes (Jorde & Figenschau, 2009;
Harris, 2005). If such a correlation between hypovitaminosis-D and hyperglycemia
exists, it creates the potential to study vitamin D supplementation as a method for
improving glucose metabolism during pregnancy (Tomedi, Simhan & Bodnar, 2013).
Insulin Resistance and Hypovitaminosis-D in Pregnancy
The normal insulin resistance of pregnancy may be compounded by the metabolic
consequences of hypovitaminosis-D which itself can contribute to insulin resistance and
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impaired glucose metabolism. A limited number of large studies have supported the
premise that maternal hypovitaminosis D during pregnancy is linked to insulin resistance,
elevated fasting blood glucose levels, or GDM (Burris et al., 2013; Jensen et al., 2013;
Maghbooli et al., 2008). Retrospective studies examining the relationship between a
diagnosis of gestational diabetes mellitus (GDM) and serum calcidiol levels failed to find
an association between hypovitaminosis-D and a diagnosis of GDM, yet the researchers
reported that they did find an association between hypovitaminosis-D and elevated blood
glucose levels (Farrant et al., 2009; Lau et al., 2011). These discrepancies are evidence
that there continues to be a gap in knowledge on the influence of hypovitaminosis-D on
glucose metabolism in pregnancy. Since pregnancy results in progressive physiological
changes, the relationship between calcidiol and blood glucose in early, mid, and late
pregnancy will be discussed.
Hypovitaminosis-D in Early Pregnancy
Scientists examining vitamin D levels in the first trimester (early pregnancy) did
not find an association between serum vitamin D and GDM. Baker et al., 2012;
Fernandez-Alonso et al., 2012; Makgoba et al., 2011; Tomedi et al., 2013; Zhang et al.,
2008). Baker et al. (2012) investigated the relationship of first trimester vitamin D
deficiency and the risk of GDM based on the premise that hypovitaminosis-D might be
related to dysfunction of pancreatic β-cells leading to impaired glucose metabolism. The
researchers used a nested case-control approach with 180 women in their sample. They
used stored serum collected in the first trimester for calcidiol levels and blood glucose
levels from the GDM screening at 24-28 weeks gestation. They were unable to prove
their hypothesis that first trimester hypovitaminosis-D was related to higher levels of
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GDM because so few of the participants in their study had hypovitaminosis-D (Baker et
al., 2012).
Fernandez-Alonso et al. (2012) examined pregnancy outcomes and first trimester
(early pregnancy) vitamin D levels for 466 women in a cross-sectional study in Spain.
Participants had a serum blood drawn between 11-14 weeks gestation at their first
prenatal visit then were followed to the end of pregnancy. Seasonal variations in vitamin
D levels were found based on the first trimester being in the spring/summer compared to
the fall/winter and this seasonal variation continued into the second trimester. They also
found a progressive and significant decrease in vitamin D levels from the first to the third
trimester which was independent of season of the year. However, perinatal outcomes did
not vary based on the calcidiol levels in the first trimester (Fernandez-Alonso et al.,
2012).
Makgoba et al. (2011) looked for an association between serum vitamin D in the
first trimester and development of GDM in a prospective, case-controlled study of 248
women. Blood samples collected in the first trimester were used from a multiethnic
group consisting of 90 women who developed GDM and a control group of 158 women.
The women in the study were receiving care in inner-city London. There was a negative
correlation between the calcidiol level at the initial prenatal visit in the first trimester and
the glucose level obtained in mid-pregnancy at a two hour glucose test. However, there
was not a statistically significant difference between the calcidiol levels in the group of
women who developed GDM when compared to the group who did not develop GDM.
Univariate analysis showed a positive association between calcidiol levels and maternal
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age and a negative association between calcidiol levels and the first trimester BMI
(Makgoba et al., 2011).
The Study of Nutrition and Pregnancy (SNAP) data was used by Tomedi et al.
(2013) to investigate the association between the calcidiol levels in early-pregnancy (< 16
weeks gestation) and the blood glucose levels collected at 24-28 weeks gestation which
was through a routine glucose screening test. They defined hypovitaminosis-D as a
serum calcidiol level < 50 nmol/L. There were 429 women in their sample. They found
that 67% of the women had hypovitaminosis-D and 11% of the women had
hyperglycemia. They did not find a difference in the calcidiol and glucose levels when
using the Pearson chi-squared or the Students’-test. They then looked at calcidiol as a
continuous variable with logistic and multivariate linear regression models to examine
the association between the maternal calcidiol levels and blood glucose levels or
hyperglycemia. Smoking status was included in the data set. Among the smokers,
calcidiol levels in the first trimester were lower for those with hyperglycemia at midpregnancy. This association was not found for the non-smokers. In their analysis, they
considered that this may be due to the attributes of their cohort (young, nulliparous, with
low incidence of GDM) or that smoking may concurrently reduce vitamin D levels and
increase blood glucose concentrations due to oxidative stress. They reported this may
have resulted in the association between hypovitaminosis-D and hyperglycemia in the
participants who smoked.
Zhang et al. (2008) used a subset of the Omega Study to investigate the
association between serum calcidiol levels in early pregnancy and the risk for GDM. The
subset consisted of 57 women with a diagnosis of GDM and 114 women without this
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diagnosis as controls out of the complete data set had a total of 953 participants. The
researchers used the Student’s t test to examine the mean calcidiol levels between the two
groups. They reported that the participants with a diagnosis of GDM had a significantly
lower serum calcidiol concentration than the control group (24.2 ng/ml vs. 30.1 ng/ml, P
< 0.001) after controlling for maternal age and BMI. They concluded that
hypovitaminosis-D in early pregnancy (< 16 weeks gestation) was associated with a
significantly increased risk for GDM. The researchers analyzed the characteristics of the
participants and reported that, in general, the women who developed GDM were older
and heavier than those who did not develop GDM. However, they report that even after
controlling for these variables, the inverse association between early pregnancy calcidiol
levels and GDM risk remained statistically significant (Zhang et al., 2008).
The studies described above demonstrate that science has not yet been able to
determine the nature of the relationship between calcidiol levels and glucose metabolism
in pregnancy. Many researchers used the diagnosis of GDM as a measure of
hyperglycemia from impaired glucose metabolism. For the purposes of this study, GDM
will be used as proxy to hyperglycemia in pregnancy.
Hypovitaminosis-D in Mid Pregnancy
Some researchers have reported an increased risk for GDM when women have
hypovitaminosis-D in the second trimester (Burris et al., 2012; Clifton-Bligh et al., 2008;
Maghbooli et al., 2008; Parlea et al., 2012; Soheilykhah et al., 2012; Yap, Gunton, Munns
& McLean, 2014). Burris et al. (2012) concluded that mid pregnancy serum vitamin
calcidiol levels were inversely associated with the blood glucose level obtained one hour
after a 50 gram glucose load. Clifton-Bligh et al. (2008) reasoned if vitamin D
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influenced insulin sensitivity or release, any effects of hypovitaminosis-D would become
apparent in later pregnancy when progressive insulin resistance affects glucose
metabolism. In their prospective study, they found a non-linear, inverse correlation
between serum vitamin D levels and fasting glucose but this significance became
borderline when they included body mass index (BMI) in the analysis (Clifton-Bligh et
al., 2008).
Maghbooli et al. (2008) found higher insulin resistance and fasting blood glucose
levels in a group of pregnant women with hypovitaminosis-D, even after adjusting for the
confounding variables of age and BMI. However, they found hypovitaminosis-D in 71%
of their sample of pregnant women and severe hypovitaminosis-D in 29% of their sample
when looking at hypovitaminosis-D and insulin resistance. They reported that
hyperglycemia during pregnancy was significantly higher in the group with severe
hypovitaminosis-D (Maghbooli et al., 2008).
Soheilykhah et al. (2010) found hypovitaminosis-D (serum calcidiol < 50 nmol/L)
in 83.3% of the participants with GDM and in 71.2% of the controls (matched in age,
BMI, and gestation). They report women with increase blood glucose levels at mid
pregnancy had significantly lower serum calcidiol levels compared with the control
group. Furthermore, women with GDM had a 2.66 fold increased risk of having serum
vitamin calcidiol levels < 37.5 nmol/L (Soheilykhah et al., 2010).
Yap et al. (2014) report there is an increased risk of gestational diabetes mellitus
associated with hypovitaminosis-D in pregnancy and postulated that high dose vitamin D
supplementation for women who had hypovitaminosis-D (defined as serum calcidiol < 80
IInmol/L) before 20 weeks gestation might decrease this risk. Participants with
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hypovitaminosis-D were randomized to receive 5,000 IU of vitamin D daily (high dose)
or 400 IU daily (low dose) and the mid-pregnancy blood glucose levels obtained from an
oral glucose tolerance test were compared. There was no difference in the mean maternal
glucose levels between the two groups. However, 8% of the participants in the high dose
group were diagnosed with GDM compared to 13% in the low dose group, and baseline
serum calcidiol showed an inverse relationship with the blood glucose levels (Yap et al.,
2014).
Hypovitaminosis-D in Late Pregnancy
There are limited studies specifically examining the relationship between
hypovitaminosis-D and hyperglycemia in pregnancy in late pregnancy. Farrant et al.
(2009) measured serum calcidiol levels and blood glucose levels at 30 weeks of gestation
in Mysore women living in India. They did not find a relationship between serum
vitamin D levels at 30 weeks of gestation and gestational diabetes mellitus (GDM) but
they did find a high level of hypovitaminosis-D in their sample. They reported that, in
women with hypovitaminosis-D, higher vitamin D levels were associated with lower BG
levels at the 30 minute interval during an oral glucose tolerance test (Farrant et al., 2009).
McLeod et al. (2012) report that insulin resistance develops in the second and
third trimesters of pregnancy and that vitamin D may affect glucose metabolism through
influence on the β cells of the pancreas. Lau et al. (2011) examined glycated hemoglobin
(HgA1c) and serum calcidiol levels in late pregnancy. They found hypovitaminosis-D in
41% of their participants and concluded lower serum calcidiol levels was associated with
impaired glucose metabolism. They reported an inverse association between the vitamin
D level and glucose control in late pregnancy or the third trimester (Lau et al., 2011).
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Cho et al. (2013) investigated the relationship between vitamin D levels drawn at
the time of birth (late pregnancy) and the blood glucose level drawn at 24-28 weeks
gestation. They found that 85% of the women diagnosed with GDM had
hypovitaminosis-D (calcidiol < 20 ng/mL) and 27.5% of the women with normal
pregnancy had hypovitaminosis-D. They concluded that there was an association
between hypovitaminosis-D and GDM (Cho et al., 2013).
It is interesting to note that the studies in the third trimester reported an inverse
association between serum vitamin D levels and blood glucose (Cho et al., 2013; Farrant
et al., 2009; Lau et al., 2011) even though these studies were methodologically different.
Cho et al. (2013) investigated serum calcidiol levels just before delivery and found a
higher incidence of hypovitaminosis-D in the women with GDM. Farrant et al. (2009)
found an association between vitamin D levels and BG levels at the 30 minute interval
during an oral glucose tolerance test, but not an association with the other blood glucose
levels in the test nor with a diagnosis of GDM. Lau et al. (2011) looked at serum
calcidiol levels at the time of a glycated hemoglobin test in the third trimester for women
with known GDM and found an inverse association between calcidiol levels and
glycemic control.
Summary
Optimal health in pregnancy requires unimpaired glucose metabolism which may
depend upon adequate levels of biologically active vitamin D. The GDM screening is a
single value at one point in time based on a protocol and the criteria for diagnosing GDM
are not consistent or have been changed periodically over the years (Coustan et al., 2010).
The pregnancy related problems of GDM are a result of hyperglycemia (Aghajafari et al.,
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2013; Desoye & Hauguel-de Mouzon, 2007; Landon et al., 2012; Vambergue & Fajardy,
2011). Researchers and clinicians are just a beginning to understand the impact of
vitamin D during pregnancy on the health of the mother and the future health of the
developing fetus (Barker, 2007; Barker & Bagby, 2010; Bergstrom, Blanck & Savendahl,
2013). Maternal hypovitaminosis-D is quite possibly a modifiable risk factor which can
be targeted to improve pregnancy outcomes and even prevent hyperglycemia in
pregnancy through the simple, cost effective use of vitamin D supplementation (Parlea et
al., 2012; Poel et al., 2012; Senti, Thiele & Anderson, 2012). Preventing
hypovitaminosis-D during pregnancy supports an optimal intrauterine environment which
may impact the health of future generations (Barker, 2005, 2007; Holt, Coleman, &
McCance, 2011).
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CHAPTER III
METHODS
Introduction
Chapter III provides details on the study design, population and sample, and
sampling procedures. Discussion includes each of the study variables which are maternal
age, body mass index (BMI), calcidiol levels at three points during pregnancy, and blood
glucose in mid-pregnancy. The data analysis process is discussed. The chapter ends with
limitation of the study.
The purpose of this study was to determine the relationship between calcidiol
levels collected in early, mid, and late pregnancy and blood glucose levels in mid
pregnancy in a sample of women in an upper Midwestern region of the United
States. Calcidiol influences glucose metabolism in the non-pregnant population (Alfonso
et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al., 2013) and this study
investigated the influence of calcidiol on glucose metabolism in the pregnant
population. Identifying the correlation between calcidiol and glucose levels may inform
the potential mechanism on the effect of calcidiol on glucose metabolism in pregnancy.
There were three research questions. 1) Is there a correlation between the calcidiol level
at 10-14 weeks gestation and the blood glucose (BG) level at 24-28 weeks gestation when
controlling for the known confounding variables of age and pre-pregnancy body mass
index (BMI)? Is there a correlation between calcidiol level at 22-26 weeks gestation and
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the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI? 3) Is there a correlation between the calcidiol level at 32-36
weeks gestation and the BG level at 24-28 weeks gestation when controlling for the
known confounding variables of age and BMI?
Research Design
A quantitative, correlational design was used in a secondary analysis to ask new
questions of an existing data set. The level of significance was set at p < .05. This study
was designed as a secondary analysis of data collected in a prior prospective study. An
advantage of this type of study design is the ability to answer new research questions of
an existing data set (Castle, 2003; Doolan & Froelicher, 2009). The primary research
was a prospective study to examine differences in women that did or did not develop
preeclampsia (Anderson, Ralph, Wright, Linggi, & Ohm, 2013). The primary study used
a convenience sample of women recruited from a community located at latitude of 47.96
degrees north (Anderson et al., 2014). The design of the parent study determined the
inclusion and exclusion criteria. Eligibility criteria included English speaking nulliparous
women who were at least 18 years of age carrying a singleton pregnancy. In addition,
participants needed to be enrolled between 10 and 14 weeks of gestation, received
prenatal care in the community, and delivered at the local community hospital. Exclusion
criteria included woman who were unable to communicate in English, were younger than
18 years of age, were not nulliparous, pregnant with multiples, or beyond 14 weeks of
gestation at time of enrollment. The data set for the secondary analysis only included
women who were followed through delivery.
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Demographic data was collected at enrollment between 10-14 weeks gestation.
Peripheral blood samples through venipuncture were drawn at 10-14 weeks gestation,
22-26 weeks gestation, and 32-26 weeks gestation. The data set acquired for the
secondary analysis included laboratory results and standard measures from the medical
record collected during prenatal care, including a blood glucose level at 24-28 weeks
gestation. The study was presented and refined based on input from stakeholders
including groups providing prenatal, labor and birth care as well as nursing staff on the
inpatient unit where the participants gave birth.
Population and Sample
This study used a convenience sample of 52 nulliparous pregnant women who
received prenatal care and delivered in a single healthcare system in an upper Midwestern
community of the United States. All of the participants in the study needed to be at least
18 years of age, nulliparous, enrolled before 14 weeks gestation, and did not have preexisting medical conditions. The participants volunteered by responding to recruitment
measures and lived in or near the upper Midwestern community. All of the women in the
study received usual prenatal care appropriate to their institution and all were followed
through delivery. The study sample was compared with the population of the state of
North Dakota which represents the region and with the population of the United States.
This was done to determine generalizability of the study findings.
Sampling Procedures
Sampling procedures are discussed below. This begins with how participants
were recruited for the study, the time points for data collection, and the process of data
collection. Protection of human subjects is discussed at the end of this chapter.
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Recruitment
Recruitment occurred through advertising using local print media, the internet, a
local television community bulletin board, and through flyers posted in the clinics which
provided ambulatory care to pregnant women in the region. One page 8x10 inch posters
were created then placed on bulletin boards in the perinatal clinic areas and on public
access bulletin boards in grocery stores and shopping areas. In addition, an
advertisement was placed in a local “shopper-style” free paper and a similar written
advertisement was run as part of scrolling announcements on a local public information
television channel. Individuals who were interested in participating in the study called
the phone number listed and were screened for eligibility by a research team member.
Those who met inclusion criteria met with a trained research assistant at the Grand Forks
Human Nutrition Research Center (GFHNRC) three times during the prenatal period.
The first meeting with the research assistant was between 10-14 weeks gestation
at which time the study was reviewed with the participant, informed consent was
obtained, and a blood sample was obtained through venipuncture. The participants
returned two more times to the GFHNRC for subsequent blood samples through
venipuncture at 22-26 weeks gestation and at 32-36 weeks gestation (Figure 3). After
giving birth, medical record abstraction was performed to obtain the height, prepregnancy weight (or weight at first prenatal medical appointment if pre-pregnancy
weight was unknown), and the blood glucose routinely obtained in mid-pregnancy
between 24-28 weeks gestation.
All participants lived in or near the upper Midwestern community. All of the
women in the study received usual prenatal care appropriate to their institution. All were
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followed through delivery. Each woman received a $75 incentive, scaled over three data
collection points, for completing the study.

Figure 3. Recruitment and collection of data.
Instrumentation
The instrumentation used in this study is discussed in detail below. Included is
the process used to obtain the serum calcidiol levels and the manner used to obtain the
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other variables. Data about race was obtained and recorded at the time of study
enrollment. The medical record was used to obtain pre-pregnancy or initial weight,
height, and blood glucose level in mid-pregnancy. Information from the medical record
was transcribed onto a tool with only the study participant number; there was no
information which could identify the participants.
Methods for Calcidiol Blood Sampling
Peripheral blood samples were collected by venipuncture in early pregnancy
(10-14 weeks gestation), mid-pregnancy (22-26 weeks gestation), and late pregnancy
(32-36 weeks gestation). Serum was extracted from the blood samples for analysis of
serum calcidiol levels. Samples were collected, processed, and stored by research staff at
the Grand Forks Human Nutrition Research Center (GFHNRC) for study enrollment and
for calcidiol levels. The participants reported to the GFHNRC at times scheduled for
data collection at each of three time points in gestation. Using appropriate universal
precautions, the research staff performed venipuncture to collect the whole blood from
the participants. The blood was collected in two red top serum separator vacutainer (BD, Franklin Lakes) blood tubes. The blood samples were kept at room temperature for
one hour to allow clotting then centrifuged for 10 minutes at 1,000 rpm at 4 degrees
centigrade. Serum was removed from the red top tubes, aliquoted (500 μl), and frozen at
-80 degrees centigrade for storage until used for analysis of the serum vitamin D levels in
the parent study.
Laboratory Analysis for Serum Calcidiol Levels
Circulating calcidiol levels were analyzed in the parent study using the
Immunodiagnostic Systems LTD (IDS) 25-Hydroyxy Vitamin D enzyme-immunoassay
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(EIA) kit for quantitative determination of calcidiol in serum (Appendix D). Samples,
controls and calibrators were diluted with biotin labelled 25-OH D. To perform the
analysis, 25 μl of serum was placed in a labelled borosilicate glass or polypropylene tube
then 1 ml of biotin solution (which dissociates the vitamin D from vitamin D binding
protein) was added and mixed by a thorough vortex for 10 seconds. A plate with
microtitre wells coated with sheep 25-OH D antibody was used and each well was filled
with 200 µL of the diluted sample. The plate was sealed and incubated for 2 hours at
room temperature (18-25 degrees centigrade). The plate was washed three times with a
specific washing solution (WASHBUF) included in the kit. Next, an enzyme conjugate
which selectively binds to the Vitamin D-biotin complex was added to each well and the
covered plate was again incubated for 30 minutes at room temperature (18-25 degrees C).
The wash step was repeated using the WASHBUF (as above), then a chromogenic
substrate was added to the samples then the reactions was stopped by the addition of a
hydrochloric acid solution. Within 30 minutes, a microtitre plate reader is used to
measure the absorbance of the stopped reactions in each well with the color intensity
inversely proportional to the 25-OH D concentration.
Laboratory Analysis of Blood Glucose
The blood glucose level was drawn during usual prenatal care at 24-28 weeks
gestation as part of screening for gestational diabetes mellitus. Women ingested a
beverage containing 50 grams of glucose, the time was noted, and a blood glucose levels
was drawn in one hour per venipuncture by clinic staff. The blood glucose testing was
analyzed in the clinic laboratory using standard operating procedures and the results were
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entered into the medical record. The blood glucose levels used in this study were
obtained from the medical record abstraction.
The blood sample is placed in either a green top or an SST tube. A label is placed
lengthwise on the tube with bar codes which contain the patient identifiers and the
laboratory test ordered. The tube is placed in a Megafuge 10 and spun at 32 revolutions
per minute for 10 minutes to separate the plasma and the red blood cells. The rubber
stopper is then removed from the tube, the tube is placed in a sample carrier, and the
sample carrier is placed in the appropriated bay of the Architect ci 8200. The machine
reads the bar code and automatically runs the remainder of the test then prints out results
for interpretation. The lab protocols include calibration of the machine every 720 days
and weekly quality control testing (personal communication, Sheila Piper, 10-6-2015).
Data Collection Procedures
The participants reported to the Grand Forks Human Nutrition and Research
Center at points for data collection. The first collection point was between 10-14 weeks
gestation and included an overview of the study, informed consent, and venipuncture for
collection of blood for subsequent vitamin D analysis. Venipuncture was repeated at
second and third collection points which were at 22-26 and 32-36 weeks gestation.
Each blood sample totaled 45 milliliters (three tablespoons) placed into two red top blood
collection tubes for subsequent serum extraction. Serum calcidiol levels were obtained
from the serum blood draws at the GFHNRC at the three data collection points—early
pregnancy, mid-pregnancy, and late pregnancy. More specifically, the data collection
points were at 10-14 weeks gestation (VitD-early), 22-26 weeks gestation (VitD-mid),
and 32-26 weeks gestation (VitD-late).
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After birth, medical record abstraction was conducted with data recorded using a
unique identification unrelated to personal participant information. The data from the
medical record included maternal age at delivery, body mass index (BMI), serum blood
glucose level at 24-28 weeks of gestation. BMI was calculated using the height and the
pre-pregnancy weight or the first weight obtained if the pre-pregnancy weight was not
available. Descriptive statistics were used to describe the study population.
Table 1. Description of Variables and Measurements.
Variable

Data Source or Measurement

Demographics

Intake information; medical record

Maternal Age

Medical record; age in years at delivery

Body Mass Index (BMI)—weight
in kilograms (kg); height in
meters (m)

Medical record; BMI = kg/m2

VitD-early

Serum vitamin D level (calcidiol) in nmol/L;
collected at 10-14 weeks gestation at GFHNRC

VitD-mid

Serum vitamin D level (calcidiol) in nmol/L;
collected at 10-14 weeks gestation at GFHNRC

VitD-late

Serum vitamin D level (calcidiol) in nmol/L;
collected at 10-14 weeks gestation at GFHNRC

Blood Glucose (BG)

Blood glucose in mg/dl; collected by clinic lab at
24-28 weeks of gestation

Data Analysis
The research questions are listed below as a reference for the discussion on data
analysis. This is followed by a description of the data set and specific variables. Finally,
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the statistical tests used in the analysis are described in detail. The level of significance
was set at p < .05 and the measure of variation was standard deviation using the formula:
.
Research Questions
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and
the blood glucose (BG) level at 24-28 weeks gestation when controlling for the known
confounding variables of age and pre-pregnancy BMI?
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the
BG level at 24-28 weeks gestation when controlling for the known confounding variables
of age and BMI?
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and
the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI?
Data Set
Data from a total of 52 participants were analyzed to test for a correlation between
serum calcidiol levels at three points in pregnancy and the blood glucose (BG) level at
mid-pregnancy. The de-identified data used in this secondary analysis was obtained in a
SAS file, transcribed onto an Excel spreadsheet, verified with the original data to ensure
accuracy, and examined for anomalies and outliers. The data set was then loaded into a
file in the Statistical Package for Social Sciences (SPSS) version 22 (IBM). These data
included serum calcidiol levels in nmol/L at 10-14 weeks gestation (VitD-early), serum
calcidiol levels in nmol/L at 22-26 weeks gestation (VitD-mid), serum calcidiol levels in
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nmol/L at 32-36 weeks gestation (VitD-late); blood glucose (BG) at 24-28 weeks
gestation; and height and weight which were used to calculate BMI and age.
The numeric value for the BMI was used as a continuous variable in the
calculations. Age was a numeric, continuous variable. The numeric value for the serum
calcidiol level was used as a continuous variable in the multiple regression analysis and
as a categorical variable (inadequate or adequate calcidiol level) for the t-test. The
numeric value for the blood glucose (BG) level was used as a continuous variable in the
statistical analysis
Descriptive Data
The race was obtained for the sample, the population (North Dakota), and the
nation (United States). In order to determine if the sample was representative of the
region and the nation, analysis of variance (ANOVA) was performed which tested the
differences between the observed and expected proportions. The results provided a basis
for generalizability of findings. This is discussed in greater detail in subsequent chapters.
Multiple Regression Analysis
Statistical analysis was performed using SPSS. A multiple regression analysis
was utilized to determine if there was a correlation between the independent variables of
VitD-early, VitD-mid, VitD-late and the dependent variable, BG. As discussed in
Chapters I and II, maternal age at delivery and BMI were known confounding variables.
To control for these confounding variables, BMI and age were also included as
independent variables in the multiple regression.
A regression analysis was the preferred statistical test to look for an association
because all of the variables were continuous in the data set used in this analysis. Data for
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each variable were checked for normality and to verify that the assumptions of the
statistical procedures were met. Assumptions for linear regression are linearity and
additivity, statistical independence, homoscedasticity (constant variance) and normality,
and these assumptions were met for the data set. A multiple linear regression was chosen
because there was more than one independent variable; a simple linear regression would
be used with a single independent and a single dependent variable.
The working hypothesis for this study was that an inverse relationship would exist
between serum calcidiol levels during pregnancy and the mid pregnancy blood glucose
levels. This hypothesis aligned with the work of other researchers, more specifically that
of Maghbooli et al. (2008), Soheilykhah, Mojibian, Rashidi, Rahimi-Saghand and Jafari
(2010), and Zhang et al. (2008). A one-tailed test was chosen to test for an inverse
relationship between serum calcidiol levels (VitD-early, VitD-mid, and VitD-late) and
the BG levels in mid-pregnancy. When interpreting results, a perfect correlation would
have been indicated by 1.00; no correlation would have been indicated by 0.00.
Independent Samples t-test
The data was coded into categories of inadequate serum calcidiol levels (presence
of hypovitaminosis-D) and adequate serum calcidiol levels. This divided the sample into
two groups (inadequate and adequate serum calcidiol levels). An independent sample ttest was used to compare means between the two groups and the BG at each of the time
points of the each of the serum calcidiol levels (VitD-early, VitD-mid, and VitD-late).
Cohen’s d was included in the statistical results.
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Trends in Serum Calcidiol Levels
Mean values for each of the calcidiol levels were determined and compared.
Trends were examined in the calcidiol levels across the three time points and the
relationship between the variables was determined. Serum calcidiol levels over the three
data collection time points were described and compared.
Association Between Confounding Variables
Pearson’s correlation coefficient was performed to evaluate the association
between the confounding variables. This included the relationship between BG and age
as well as the relationship between BG and BMI. It also included the relationship
between BMI and serum calcidiol levels, and the relationship between age and the serum
calcidiol level.
Protection of Human Subjects
Protection of human subjects was assured. The parent study received Institutional
Review Board (IRB) approval by the University of North Dakota IRB and the Altru
Health System IRB (Appendix A). Informed consent (Appendix B) was obtained upon
enrollment in the parent study which included the variables used in the secondary
analysis. Each participant received both written and verbal study information. All were
reassured that their medical care was the same whether or not they chose to participate in
the study and that there was no obligation to participate. All participants received the
usual and customary care provided at their respective institutions. Since the goal of this
study was to identify factors exclusive to pregnant women, enrollment of children was
inappropriate.
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IRB approval was submitted to perform the secondary analysis for this study to
both UND and Altru Health System (Appendix A). The project was approved by both
agencies and considered an Exempt Review since it was a secondary analysis of a deidentified data and the parent study had previously received IRB approval from both of
these same IRBs. According to Doolan and Froelicher (2009), a secondary analysis of an
existing data set has the benefit of answering new research questions without putting
participants at risk for any harm. Further protection of human subjects is provided from
the study design being a secondary analysis of a de-identified data set. The information
from the medical record was transcribed onto a Medical Record Abstraction Form
(Appendix C) which did not include any identifying information about participants.
Linkage between personal identification and unique identification number was known
only to the principle investigator of the parent study. The data set used in this secondary
analysis was de-identified.
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CHAPTER IV
RESULTS
Introduction
The relationship between calcidiol levels at three predetermined points in
pregnancy and the blood glucose level at 24-28 weeks gestation are reported. This
chapter reports the descriptive statistics for the sample participants and the results of the
multiple regression analysis to answer each of the research questions. A comparison of
the calcidiol levels at each of the three collection points is reported. The relationship
between the variables used in the analysis was determined and reported in this chapter.
Finally, the sample findings are compared with the regions, the state, and the nation.
Descriptive Statistics of the Sample Participants
This section describes the characteristics of the sample participants as it relates to
the study variables. Age and body mass index (BMI) are known confounding variables
so are both presented. Included is a normal distribution curve to illustrate how the
sample aligns with a normal distribution. Then the race of the sample participants is
discussed and compared with that of the region (the state of North Dakota) and the nation
(United States) as these demographics influence the generalizability of the findings from
this sample.
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Age
The age range in years for the 52 participants in this study was between 18.8 and
35.8 years with a mean of 25.9 (+ 4.18). The normal childbearing age is between 18 and

Number of Participants

35 years and are within the expected range and normal distribution (Figure 4).

Age in Years
Figure 4. Distribution of age in sample.
Table 2. Age and Body Mass Index.
Minimum

Maximum

Mean

SD

Age (years)

18.8

35.8

25.9

4.18

BMI (kg/m2)

19.3

39.4

27.2

5.08

Body Mass Index (BMI)
The BMI was calculated for each of the participants. As a group, the sample was
in the overweight category which was determined because the mean BMI was 27.2 kg/m2
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(+ 5.08). BMI for the sample ranged from 19.3 to 39.40 kg/m2 which indicated the
sample had women of normal BMI to women in the obese category for BMI. There were
no participants with a BMI in the underweight category. A histogram was created to
examine the frequency and distribution of the BMI values for the sample and the normal

Number of Participants

distribution Bell curve was place over the histogram (Figure 5).

Body Mass Index (BMI)
Figure 5. Distribution of BMI in sample.
Race of Study Participants
The participants were asked to self-report their race with the following results:
92.3% (n=48) Caucasian, 1.9% (n=1) Hispanic, and 5.8% (n=3) “mixed race” (Figure 6).
The sample is closely representative of the population in North Dakota which has the
following statistics on race: 89.6% Caucasian, 2.9 % Latino or Hispanic, 2 % black or
African American, 5.4 % American Indian and Alaska Native, 1.2 % Asian, and 1.9 %
“mixed race” indicating two or more races (United States Census Bureau, 2013). There
were no Native American or African-American participants. This is important because
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there is a higher prevalence of impaired glucose metabolism during pregnancy in Native
American, African-American, and Hispanic women in the United States than in nonHispanic white women (Alzaim & Wood, 2013). Barriers for minority participation in
research studies include access to care, false perceptions, mistrust (Fisher & Kalbaugh,
2011) and personal circumstances such as job flexibility or lack of awareness about the
study (Wendler et al., 2006).

Figure 6. Race of sample and of North Dakota population.

Figure 7. Race of sample, North Dakota population, and of the United States.
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Table 3. Race of Sample and Population.

Self-reported race

Sample

North Dakota United States

Total people

52

723,857

316,497,531

White alone

92.3% (n=48)

89.6%

77.7%

1.9% (n=1)

2.9%

17.1%

Black/African American alone

0%

1.8%

13.2%

American Indian/Alaska Native

0%

5.4%

1.2%

Asian alone

0%

1.2%

5.3%

5.8% (n=3)

1.9%

2.4%

Latino or Hispanic

Two or more races

N=52 in study sample. North Dakota and United States per United States Census Bureau,
2013
The ethnicity was obtained for the sample, the population (North Dakota), and the
nation (United States) and is reported above (Figure 7 and Table 11) (United States
Census Bureau, 2013). ANOVA was performed to ascertain if the study sample was
representative of the population and the nation by testing for the difference between three
groups (sample, North Dakota, and United States) the observed and expected proportions.
There was not a statistically significant difference between groups at the p< .05 level,
F(2, 15) = 01, p = .99.
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Blood Glucose Levels
Women are at risk for hyperglycemia during pregnancy due to the physiological
changes which occur. Blood glucose levels are obtained at mid-pregnancy in the normal
course of prenatal care to screen for hyperglycemia. For the purposes of this study, the
blood glucose (BG) levels in mg/dl acquired at the routine mid-pregnancy test were
collected through medical record abstraction. The results are summarized below.
In this sample, 5.8 % of the participants had a BG >140 mg/dl. The mean for BG
for the sample was 93.8 (+ 20.41 standard deviation). As illustrated in Figure 8, this
histogram of BG results is plotted with an overlay of a normal distribution Bell curve.
This demonstrates that the scores generally follow a normal distribution. There is a
negative skew showing that the sample had a higher frequency of BG results which were
less than 100 mg/dl. It is visually apparent that the actual frequency of BG values was
highest between 75 mg/dl and 100 mg/dl. The significance of this finding will be
discussed in Chapter V.
Table 4. Summary of Study Sample Findings for Blood Glucose.

BG (mg/dl)

Minimum

Maximum

Mean

SD

59.0

157.0

93.8

20.42

Serum Calcidiol Levels
Blood was collected through venipuncture at three pre-determined points in this
study to obtain serum calcidiol levels. As discussed previously, serum calcidiol is the
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Number of Participants

Blood Glucose Levels (mg/dl)
Figure 8. Distribution of blood glucose at 24-28 weeks of gestation in sample.
usual laboratory test to determine vitamin D status. For the purposes of this study,
hypovitaminosis-D was defined as a serum calcidiol level of < 75 nmol/L.
Prevalence of Hypovitaminosis-D in Sample
Calcidiol levels for the sample for each of the collection points were examined.
Only fifteen percent of the study participants had adequate calcidiol levels at all three of
the points measured. Hypovitaminosis-D was present in 81% of the participants at one or
more points during the pregnancy and 67.3% with hypovitaminosis-D at all three
measurement points. In early pregnancy (VitD-early), 41 out of 52 women (78.9%) had
hypovitaminosis-D. In mid pregnancy (VitD-mid), 40 out of the 52 women (77%) had
hypovitaminosis-D and in late pregnancy (VitD-late), 37 out of the 52 (71%) of the
participants in the sample had hypovitaminosis-D (Figure 9).
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Figure 9. Number of participants by calcidiol level greater or less than 75 nmol/L.
Range of Calcidiol Levels in Sample
The range in the calcidiol levels demonstrates that some participants had levels
much higher than 75 nmol/L. VitD-early ranged 41.6-123.5 nmol/L, VitD-mid ranged
36.5-154.3 nmol/L, and VitD-late ranged from 25.3-182.8 nmol/L. The mean at each of
these points for the sample was < 75 nmol/L which indicates that there were inadequate
calcidiol levels at all points in pregnancy for this sample, as a whole. The mean calcidiol
level was 63.3 nmol/L for VitD-early, 66.3 nmol/L for VitD-mid, and 66.4 nmol/L for
VitD-late (Table 5).
Scatterplot of Participant and Target Calcidiol Levels
Figure 10 visually demonstrates the calcidiol levels in nmol/L for each participant
at each of the three collection points (VitD-early, VitD-mid, and VitD-late) compared to
target level of greater than or equal to 75 nmol/L. It is evident that the majority of serum
calcidiol levels were less than the target level. A few participants had at calcidiol levels
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Table 5. Summary of Study Sample Findings of Calcidiol.
Minimum

Maximum

Mean

SD

Vit D-early (nmol/L)

41.6

123.5

63.3

19.5

Vit D-mid (nmol/L)

36.5

154.3

66.3

20.6

Vit D-late (nmol/L)

25.3

182.8

66.4

24.5

much lower than the target and a few had a calcidiol level much higher than the target
level. The clustering of calcidiol levels between 40 and 75 nmol/L emerged as one of the
limitations of the study.

Figure 10. Serum calcidiol levels for each participant at each time point.
Serum Calcidiol Levels Over Time
The mean of the calcidiol levels at each of the three collection points illustrates
that the calcidiol level for the sample slightly increased over time (Figure 11). The mean
of the serum calcidiol level at 10-14 weeks gestation (VitD-early) was 63.3 nmol/L (+
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2.7). The mean serum calcidiol level at 22-26 weeks gestation (VitD-mid) was 65.7
nmol/L (+ 2.8). The mean calcidiol level at 32-36 weeks of gestation (VitD-late) was
65.9 nmol/L (+ 3.4).

Figure 11. Mean of serum calcidiol levels at each time point (VitD-early, VitD-mid, and
VitD-late). Error bars represent standard deviation.
Frequency Distribution of Calcidiol Levels Over Three Collection Points
Although the mean calcidiol levels at the three collection points have a
mathematical difference of 2.6, the frequency distribution changes. This distribution
moves from being skewed to the left at VitD-early to a more normal distribution at VitDmid and VitD-late (see Figures 12, 13, and 14). When all of the serum calcidiol levels
are analyzed for frequency of occurrence, the distribution has a negative skew (Figure 15)
with the majority of the levels lower than the recommended level of 75 nmol/L.
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Number of Participants

Serum Calcidiol Levels (nmol//L)

Number of Participants

Figure 12. Distribution of serum calcidiol levels at 10-14 weeks gestation (VitD-early).

Serum Calcidiol Levels (nmol/L) VitD-mid
Figure 13. Distribution of serum calcidiol levels at 22-26 weeks gestation (VitD-mid).
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Number of Participants
Number of Participants

Serum Calcidiol Levels (nmol/l)
Figure 14. Distribution of calcidiol levels at 32-36 weeks gestation (VitD-late)

Serum Calcidiol Levels (nmol/L)

Figure 15. Distribution of All Calcidiol Levels in the Sample and Normal Curve. Arrow
is placed at Level of Adequate Calcidiol Level of 75 nmol/L
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Correlation in Calcidiol Levels
The trend in the calcidiol levels was analyzed to look for changes over the course
of pregnancy. Data were interval and normally distributed so the Pearson correlation was
utilized. There was a statistically significant correlation (p < 0.05) between the calcidiol
levels at each point when compared to the other calcidiol levels for the participants in this
sample. However, there was not a statistically significant change in the calcidiol levels
over the three collection points (table 6).
Table 6. Pearson Correlation Showing the Trend in Calcidiol Levels.
VitD-early

VitD-mid

VitD-early

---

VitD-mid

.87*

---

VitD-late

.83*

.95*

VitD-late

---

* Significant at p < .05
Research Questions and Analysis
This section will focus on the three specific research questions for the study.
Multiple regression analysis was utilized to look for a correlation between the calcidiol
levels at each of the three predetermined points in time and the blood glucose levels at
mid-pregnancy while controlling for the known confounding variables of age and BMI.
The findings from analysis will also be presented.
Correlation of Early Calcidiol Level With Mid Pregnancy Glucose Level
R-squared is a statistical value which reflects how closely the data fit the
regression line reported between zero (0% correlation) and one (100% correlation). The
65

amount of variation explained by the regression analysis was 8.4% as evidenced by the R
Square of 0.084 (Table 7). There was not a statistically significant correlation between
the calcidiol level at VitD-early and BG when controlling for the known confounding
variables of age and BMI. The null hypothesis was that there is no relationship between
calcidiol levels at VitD-early and BG at 24-28 weeks gestation when controlling for age
and BMI. These results failed to reject the null hypothesis for this research question.
Correlation of Mid Pregnancy Calcidiol Level With Mid Pregnancy Glucose Level
The amount of variation explained by the regression analysis was 7.1% as
evidenced by the R Square of 0.071 (Table 7). There was not a statistically significant
correlation between the calcidiol level at VitD-mid and BG when controlling for the
known confounding variables of age and BMI. The null hypothesis was that there is no
relationship between calcidiol levels at VitD-mid and BG at 24-28 weeks gestation when
controlling for age and BMI. These results failed to reject the null hypothesis for this
research question.
Correlation of Late Pregnancy Calcidiol Level With Mid Pregnancy Glucose Level
The amount of variation explained by the regression analysis was 7.5% as
evidenced by the R Square of 0.075 (Table 7). There was not a statistically significant
correlation between the calcidiol level at VitD-late and BG when controlling for the
known confounding variables of age and BMI. The null hypothesis was that there is no
relationship between calcidiol levels at VitD-late and BG at 24-28 weeks gestation when
controlling for age and BMI. These results failed to reject the null hypothesis for this
research question.
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Table 7. R Square Analysis of VitD-early, VitD-mid, VitD-late With BG When
Controlling for Age and BMI.
R

R Square

Std. Error

VitD-early and BG

.29

.08

20.1

VitD-mid and BG

.27

.07

20.2

VitD-late and BG

.27

.08

20.2

Constants: Age, BMI

Comparison of BG With Two Groups
The data was divided into two groups, inadequate serum calcidiol levels and
adequate serum calcidiol levels. An inadequate serum calcidiol level was defined as
being less than 75 nmol/L or the level of hypovitaminosis-D in this study. The two
groups were compared to see if there was a difference in the mean blood glucose levels
between inadequate and adequate serum calcidiol levels. This comparison was done for
each of the time points (VitD-early, VitD-mid, and VitD-late).
Comparison of BG With Inadequate or Adequate Calcidiol in Early Pregnancy
An independent samples t-test was conducted to compare BG in conditions of
inadequate and adequate calcidiol levels at VitD-early (using the customary p < .05). The
independent sample t test showed that the difference in the BG levels between the group
with inadequate calcidiol levels (n = 41, M = 95.78, SD = 22.05) and the group with
adequate calcidiol levels (N = 11, M = 86.36, SD = 10.20) was not statistically
significant, t(50) = 1.37, p = .18. These results suggest that there was not a statistically
significant difference in the BG between the two groups, the group with inadequate
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calcidiol levels and the group with adequate calcidiol levels at VitD-early (table 8).
Cohen’s effect size (d = .47) suggested a moderate practical significance.
An ANOVA was employed with similar results. The difference between the
means was not statistically significant at the .05 level (F= .71, df = 9, 40). The critical
value of F for the .05 level was 2.82. Since the observed value of F was less than the
critical value, the null hypothesis was not rejected.
Table 8. Mean Blood Glucose (BG) in mg/dl for Two Groups at 10-14 Weeks Gestation.
N

Mean BG level

Standard Deviation

Inadequate calcidiol

41

95.78

22.05

Adequate calcidiol

11

86.36

10.20

Comparison of BG With Inadequate or Adequate Calcidiol in Mid Pregnancy
An independent samples t-test was conducted to compare BG at 24-28 weeks of
gestation in conditions of inadequate and adequate calcidiol levels at 22-26 weeks of
gestation (VitD-mid). An independent sample t test showed that the difference in the BG
levels between the group with inadequate calcidiol levels (N = 39, M = 95.67, SD =
22.30) and the group with adequate calcidiol levels (N = 13, M = 88.15, SD = 12.29) was
not statistically significant, t(50) = 1.15, p = .25. These results suggest that there was not
a statistically significant difference in the BG between the two groups, the group with
inadequate calcidiol levels and the group with adequate calcidiol levels at 22-26 weeks of
gestation (table 9). Cohen’s effect size (d = .37) suggested a small to moderate practical
significance.
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An ANOVA was employed with similar results. The difference between the
means was not statistically significant at the .05 level (F = .28, df = 9, 40). The critical
value of F for the .05 level was 2.82. Since the observed value of F was less than the
critical value, the null hypothesis was not rejected
Table 9. Mean Blood Glucose (BG) for Two Groups at 22-26 Weeks Gestation.
N

Mean BG level

Standard Deviation

Inadequate calcidiol

39

95.67

22.30

Adequate calcidiol

13

88.15

12.29

Comparison of BG With Inadequate or Adequate Calcidiol in Late Pregnancy
An independent samples t-test was conducted to compare BG at 24-28 weeks of
gestation in conditions of inadequate and adequate calcidiol levels at 32-36 weeks of
gestation (VitD-late). An independent sample t test showed that the difference in the BG
levels between the group with inadequate calcidiol levels (N = 37, M = 95.51,
SD = 21.19) and the group with adequate calcidiol levels (N = 15, M = 89.53, SD =
18.33) was not statistically significant, t(50) = 0.96, p = .34. These results suggest that
there was not a statistically significant difference in the BG between the two groups, the
group with an inadequate calcidiol level and the group with adequate calcidiol levels at
32-36 weeks of gestation (Table 10). Cohen’s effect size value (d = .29) suggested a
small practical significance.
An ANOVA was employed with similar results. The difference between the
means was not statistically significant at the .05 level (F= .22, df = 9, 40). The critical
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value of F for the .05 level was 2.82. Since the observed value of F was less than the
critical value, the null hypothesis was not rejected.
Table 10. Mean BG for Two Groups at 32 – 36 Weeks Gestation.
N

Mean BG level

Standard Deviation

Inadequate calcidiol

37

95.51

21.19

Adequate calcidiol

15

89.53

18.33

Specifically, these results suggest that there was not a statistically significant difference
at any of the three points in pregnancy (VitD-early, VitD-mid, and VitD-late) in the BG
level at 24-28 weeks gestation between the two groups based on inadequate calcidiol
levels and adequate calcidiol levels.
Confounding Variables
Two confounding variables were often used in the literature review in the analysis
of the relationship between serum calcidiol levels and blood glucose levels during
pregnancy. Those two confounding variables were maternal age and BMI. Based on the
literature review, both age and BMI were considered confounding variables in this study.
These confounding variables were investigated separately below. First, the relationship
between BG and the confounding variables of age and BMI were investigated. Then the
relationship between the confounding variables of age and BMI and the serum calcidiol
levels were examined. The Pearson’s r is a measure of effect size in this correlation.
Effect size is small when r is 0.2, medium when r = 0.5, and large when r > 0.8 (Sullivan
& Feinn, 2012). Pearson’s r varies from -1 to 1 with the strength of the linear
relationship getting stronger as the value is closer to 1 and weaker as the value
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approaches zero. The relationship can be either positive or negative which is represented
by the positive or negative value of the integer.
Relationship Between BG and the Variables of BMI and Age
Since age and BMI are known confounders of BG metabolism, each of these
factors (age and BG; BMI and BG) were examined independently. Data were interval
and normally distributed. To determine if there was a relationship between BG and BMI,
Pearson’s correlation was computed (Table 10). There was not a statistically significant
correlation between the BG and BMI, r = 0.25, n = 52, p = .07. To determine if there was
a relationship between BG and age, Pearson’s correlation was computed (table 11).
There was not a statistically significant correlation between BG and age, r = 0.07, n = 52,
p = .60. In this sample, neither of the confounding variables of BMI and age had a
statistically significant correlation with BG.
Correlation Between BMI and Calcidiol Levels in Early, Mid, and Late Pregnancy
First, a Pearson correlation coefficient was computed to assess the relationship
between BMI and VitD-early. There was a statistically significant negative correlation
between the two variables of BMI and VitD-early, r = -0.43, n = 52,
p = .001. Second, a Pearson correlation coefficient was computed to assess the
relationship between BMI and VitD-mid. There was a statistically significant negative
correlation between the two variables, BMI and VitD-mid, r = -0.30, n = 52,
p = .03. Finally, a Pearson correlation coefficient was computed to assess the
relationship between BMI and VitD-late. There was not a statistically significant
relationship between the two variables of BMI and VitD-late, r = -0.20, n = 52, p = .16.
Overall, there was a negative correlation found between BMI and the calcidiol level at
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VitD-early and VitD-mid in pregnancy, but not found at VitD-late in pregnancy. In other
words, a higher BMI at the beginning of pregnancy was associated with a lower serum
calcidiol level in early and mid-pregnancy (Table 11).
Correlation Between Age and Serum Calcidiol Level
A Pearson correlation coefficient was computed to assess the relationship between
age and calcidiol levels at each of the three points. There was not a statistically
significant relationship at any of the three points (Table 11). In summary, age did not
have a statistically significant correlation with the calcidiol levels.
Table 11. Correlations All Factors.
Age

VitD-early

VitD-mid

VitD-late

BG

BMI

--

Age
VitD-early

- .22

--

VitD-mid

- .23

.86*

--

VitD-late

- .22

.80*

.95*

--

BG

- .07

- .16

- .12

- .12

--

BMI

.12

- .43*

- .30*

- .20

.25

--

* Correlation is significant at the 0.05 level.

Summary
The relationship between calcidiol levels in early, mid, and late gestation and
blood glucose levels at 24-28 weeks gestation was investigated in a sample of pregnant
women in an upper Midwestern community. The known confounding variables of
maternal age and body mass index (BMI) were included in the analysis.
Hypovitaminosis-D during pregnancy was found in 81% of the women and there was not
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a statistically significant change in serum calcidiol levels for the participants over time as
measured by the three collection points. Serum calcidiol levels were drawn at three
predetermined points in pregnancy and described as VitD-early, VitD-mid, and VitD-late
for the purposes of analysis. The mean of the calcidiol level at VitD-early was 63.3
nmol/L, the mean of the calcidiol level at VitD-mid was 65.7 nmol/L, and the mean
calcidiol level at VitD-late was 65.9 nmol/L. The mean calcidiol at each of these time
points was below the recommended level of 75 nmol/L. There was no evidence of a
statistically significant relationship between the blood glucose level at 24-28 weeks of
gestation and the calcidiol level at any of the predetermined points during pregnancy
(VitD-early, VitD-mid, and VitD-late) when controlling for the confounding variables of
age and BMI. There was not a statistically significant difference in blood glucose levels
between the group with inadequate calcidiol levels and the group with adequate calcidiol
levels at any of the three points.
The confounding variables were examined in relation to serum calcidiol levels
and blood glucose levels. There was a statistically significant inverse relationship
between BMI and VitD-early (p < .05), and between BMI and VitD-mid (p < .05). There
was not a statistically significant between BMI and calcidiol levels in late pregnancy.
Age did not have a statistically significant relationship with calcidiol at any point or with
BMI. A statistically significant relationship did exist between the calcidiol levels at
VitD-early, VitD-mid, and VitD-late as well as between BMI and calcidiol levels. The
study results will be discussed further in Chapter V.
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CHAPTER V
DISCUSSION
Introduction
Chapter V briefly reviews the current study, presents the findings of this research,
and integrates the results with the current literature. The discussion includes the rationale
which influenced the research based decisions, the characteristics of the sample, and
additional findings beyond the specific research questions. This chapter concludes with
limitations of the study, recommendations for further research, and implications for
nursing.
Summary of the Study
This chapter begins with a brief overview of the problem. The harmful effect of
hyperglycemia in pregnancy is highlighted. The potential mitigating influence of
calcidiol on hyperglycemia is introduced.
Overview of the Problem
Hyperglycemia during pregnancy can result in adverse outcomes for the mother
and the infant with both short term and long term consequences (Pridjian & Benjamin,
2010). The fetus obtains glucose through the placenta by facilitated diffusion (Day,
Cleal, Lofthouse, Hanson, & Lewis, 2013) and is therefore dependent upon maternal
blood glucose levels (Barta & Drugan, 2010). Even though fetal BG levels are 15 mg/dl
lower than the maternal BG levels (Gabbe et al., 2012, p. 542), increased maternal BG
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levels have been associated with fetal effects such as overgrowth (The HAPO Study,
2009). Intrauterine hyperglycemia not only results in this abnormal fetal growth but also
appears to predispose the offspring for abnormal glucose tolerance later in life (Clausen
et al., 2008; Luo et al., 2010). The persistent effects of hyperglycemia in pregnancy may
even have generational effects (Vambergue & Fajardy, 2011).
Interventions which can reduce the harm of hyperglycemia are needed. There is
growing evidence that vitamin D influences glucose metabolism. Hypovitaminosis-D has
been associated with impaired glucose metabolism in non-pregnant and pregnant subjects
which is of interest since hypovitaminosis-D can be treated through use of supplements
(Alzaim & Wood, 2013). However, the findings on the effects of vitamin D on maternal
glucose levels during pregnancy are inconsistent leading to the need for further research.
Purpose Statement
The purpose of this study was to determine the relationship between calcidiol
levels collected in early, mid, and late pregnancy and blood glucose levels in mid
pregnancy in a sample of women in an upper Midwestern region of the United States. A
quantitative, correlational design was used in a secondary analysis to ask new questions
of an existing data set. Calcidiol influences glucose metabolism in the non-pregnant
population (Alfonso et al., 2009; Mathieu et al., 2005; Pittas et al., 2006; Tohidi et al.,
2013) and this study investigated the influence of calcidiol on glucose metabolism in the
pregnant population. The significance of this relationship is that it may inform an
understanding of the effect of calcidiol on glucose metabolism in pregnancy. By
identifying the correlation between calcidiol and glucose levels, there is the potential to
mitigate hyperglycemia in pregnancy and improve the health of infants and mothers. The
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working hypothesis for this study was that there would be an inverse relationship
between calcidiol during pregnancy and mid pregnancy blood glucose levels.
In the professional literature, both maternal age and body mass index (BMI) were
considered to be confounding variables in the analysis of calcidiol and BG (Clifton-Bligh
et al., 2008; Maghbooli et al., 2008). Consistent with the literature, both BMI and
maternal age were considered confounding variables in the current study. This research
was designed to answer the following questions on the relationship between calcidiol and
BG in the sample group:
Research Questions
This section begins with the research questions answered by this study. The
methodology is then reviewed and the major findings are presented. The research
questions were:
1. Is there a correlation between the calcidiol level at 10-14 weeks gestation and
the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and pre-pregnancy body mass index (BMI)?
2. Is there a correlation between calcidiol level at 22-26 weeks gestation and the
BG level at 24-28 weeks gestation when controlling for the known confounding variables
of age and BMI?
3. Is there a correlation between the calcidiol level at 32-36 weeks gestation and
the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI?
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Review of the Methodology
This exploratory study was done to examine the relationship between serum
calcidiol levels at early, mid, and late pregnancy and the BG levels at 24-28 weeks
gestation. A secondary analysis was completed on a data set from a prospective study
which used a convenience sample of 52 pregnant women. All participants were
nulliparous women enrolled at less than 14 weeks gestation to allow the early pregnancy
calcidiol level collected at 10-14 weeks gestation. The sample population was drawn
from a community in the upper Midwestern United States at a latitude of 47.93° N.
People living at this latitude are at risk for hypovitaminosis-D because the cutaneous
production of vitamin D is limited due to the UV spectrum (Holick & Chen, 2008;
Schroth et al., 2005). The population of the state has a 31% obesity rate (Levi, Segai,
Laurent & Raybum, 2014) which is significant because obesity is associated with
hypovitaminosis-D (Hemmings, 2013; Schwanlfenberg, 2007).
In the professional literature, both maternal age and body mass index (BMI) were
considered to be confounding variables when investigating calcidiol and BG levels
(Clifton-Bligh et al., 2008; Maghbooli et al., 2008). Lower calcidiol levels can be a result
of increased BMI and increasing age can result in lower calcidiol levels (Collins-Fulea et
al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts et al., 2011). Concurrently, both
maternal age and BMI can influence maternal glucose levels. Maternal age greater than
30 years and maternal BMI in the obese category (> 30) are risk factors for
hyperglycemia in pregnancy (Soheilykhah et al., 2010; Zhang et al., 2008). Consistent
with the literature, both BMI and maternal age were considered confounding variables in
this study.
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Major Findings
There was no evidence of a statistically significant relationship between calcidiol
levels at any of the three points and the blood glucose levels when controlling for the
known confounding variables of BMI and age (R square .084, .071, and .075
respectively). However, the high percentage of hypovitaminosis-D resulted in inadequate
variance in this sample to show a difference, if one does exist. Eighty-one percent of the
participants had hypovitaminosis-D at some point during pregnancy and 67% had
hypovitaminosis-D at all three points during pregnancy.
There was a statistically significant correlation among the calcidiol levels at the
three collections points (p < 0.01). In other words, maternal calcidiol levels did not
statistically change over the course of pregnancy in this sample. The women who had
hypovitaminosis-D in early pregnancy continued to have hypovitaminosis-D in mid and
late pregnancy. These findings suggest that women who have hypovitaminosis-D in
pregnancy may not experience improvement in vitamin D levels over the course of
pregnancy.
There was a statistically significant inverse relationship between BMI and the first
(p < 0.01) and second (p < 0.05) calcidiol levels. These results suggest that women with
a higher BMI may need additional vitamin D during pregnancy. Cumulatively, these
findings suggest that women in the upper Midwest may not be getting adequate vitamin
D during pregnancy, especially those with a higher BMI.
Findings Related to the Literature
Each of the three research questions are discussed below and integrated into the
literature. First, the confounding variables of maternal age and body mass index are
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briefly discussed. This is followed by a more extensive discussion on the more complex
topics of blood glucose and calcidiol.
Maternal Age
Maternal age is a known confounding variable in the relationship between
calcidiol levels and BG levels. Increasing maternal age can result in lower calcidiol
levels (Collins-Fulea et al., 2012; Holmes et al., 2009; Prentice, 2008; Wicherts et al.,
2011). Maternal age greater than 30 years is a risk factors for hyperglycemia in
pregnancy (Soheilykhah et al., 2010; Zhang et al., 2008). The age range in this study was
18.82 years to 35.80 years with a mean age of 25.87 (+/- 5.13) years. There was not a
statistically significant correlation between maternal age and blood glucose (p = .31) nor
was there a statistically significant relationship between maternal age and the calcidiol
level at 10-14 weeks gestation (p = .12), maternal age, maternal age and the calcidiol
level at 24-28 weeks gestation (p = .10), or maternal age and the calcidiol level at 32-28
weeks gestation (p = .12).
Body Mass Index
Excess weight in early pregnancy is associated with adverse complications and
places the woman in the high risk category for perinatal management (Bautista-Castano,
Henriquez-Sanchez, Garcı´a-Herna´ndez, & Serra-Majem, 2013). A higher BMI is
associated with an increased risk of insulin resistance and impaired glucose metabolism
during pregnancy (Alberico et al., 2014; Power & Thomas, 2011; Rao, Disraeli &
McGregor, 2004). A body mass index (BMI) below 18.5 is considered underweight, 18.5
- 24.9 is categorized as normal, 25.0 – 29.9 is in the obese category, and 30.0 and above
is obese (CDC, n.d.).
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Since there is a predictable and expected weight gain during pregnancy, the
participant’s height and either pre-pregnancy weight or first documented weight in early
pregnancy were used to calculate the pre-pregnancy BMI using the formula: weight (kg) /
[height (m)]2 (CDC, n.d.). In this study, the mean BMI was 27.21 which is in the
overweight category. Two of the three women in the study sample with hyperglycemia
had a BMI which put them in the overweight category and the third had a BMI in the
obese category.
BMI is considered a confounding variable for serum calcidiol levels because
vitamin D is fat soluble and stored in adipose tissue (Achkar et al., 2015; Aloia, 2011;
Hemmings, 2013; Holick, 2004). As the amount of body fat increases, there is
progressive decrease in serum calcidiol levels (Arunabh, Pollack, Yeh & Aloia, 2003)
from irreversible sequestration of vitamin D in the adipose tissue which leads to
hypovitaminosis-D, especially if the BMI is > 30 (Hemmings, 2013; Schwalfenberg,
2007). The vitamin D insufficiency associated with obesity may occur because the
increased amount of subcutaneous adipose tissue may prevent release of stored vitamin D
(Wortsman, Matsuoka, Chen, Lu & Holick, 2000). A statistically significant inverse
relationship was found between the calcidiol level at the first and second points during
pregnancy and the BMI. Pearson’s correlation between VitD-early (the calcidiol level at
10-14 weeks gestation) and BMI was -0.43 (p = .001). Pearson’s correlation between
VitD-mid (the calcidiol level at 24-28 weeks gestation) and BMI was -0.30
(p = .03). Pearson’s correlation between VitD-late (the calcidiol level at 32-36 weeks
gestation) and BMI was -0.20 (p = .16). These findings are is consistent with the findings
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of other researchers who have found an inverse association between calcidiol levels and
BMI (Burris et al., 2012; Ding et al., 2014; Zhang et al., 2008).
Burris et al. (2012) had similar findings in their research with a large sample size
in a healthy population. They considered the possibility that hypovitaminosis-D might be
part of the causal pathway between obesity and gestational diabetes mellitus. They
suggest that vitamin D supplementation for obese women in pregnancy might decrease
the risk of developing GDM. Although they did not study pregnant women, Ding et al.
(2014) found a negative association between BMI and serum calcidiol levels (p= 0.002)
in a cross-sectional study conducted in healthy Chinese adults with normal glucose
metabolism. Zhang et al. (2008) completed a nested case controlled study examining
factors related to the development of GDM. They found that maternal serum calcidiol
levels were inversely associated with pre-pregnancy BMI (p =.01 in controls; p = .04 in
those with GDM). The study methodologies, population studied, and sample sizes all
differed in these studies but had similar results in finding an inverse association between
serum calcidiol levels and BMI in healthy people.
North Dakota ranks 14th in the United States for adult obesity with 31% of adults
in the state classified in this category (Centers for Disease Control and Prevention, 2012).
Grand Forks County where the most of the participants for this study resided, has a
median adult obesity rate of 7.1% (CDC, 2012). Since the people in this region already
ranks high in obesity, there needs to be heightened awareness of importance of adequate
vitamin D in pregnancy for women with a higher BMI.
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Blood Glucose
Blood glucose is an essential element in this study because hyperglycemia during
pregnancy can result in harm. The effects of hyperglycemia in pregnancy are presented
first. This is followed by a discussion of blood glucose as it pertains to the current study.
Effects of Hyperglycemia in Pregnancy
There are multiple dimensions to hyperglycemia which can impact the mother and
her baby including an increased risk of an adverse outcome to the pregnancy (Santamari
et al., 2011) because blood glucose levels during pregnancy have a significant influence
on both maternal and fetal morbidity (Flack, Ross, Ho, & McElduff, 2010) and long-term
effects exist beyond the newborn period and may contribute to the increasing rates of
obesity, glucose intolerance, and diabetes in the future (Lehnen et al., 2013; Luo et al.,
2010; Ryan, 2012; Veeraswamy et al., 2012).
Rationale for Choice of Blood Glucose Level
Consistent with the American Diabetes Association (2015), a normal blood
glucose level at 24-28 weeks of <140 mg/dl was considered to be normal and a level
greater than this was considered hyperglycemia. Much of the professional literature
reports on impaired glucose metabolism in pregnancy or on GDM but not specifically on
hyperglycemia in pregnancy. For the purposes of this study, GDM or impaired glucose
metabolism were considered to be proxy to hyperglycemia in pregnancy.
Blood Glucose in This Study
There were a total of 52 study participants. Three participants (5.8%) had a blood
glucose level > 140 mg/dl which was the defining point for hyperglycemia. This level is
consistent with other results in the region. In 2013, 5.1% (n=544) North Dakota residents
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had a diagnosis of GDM during pregnancy according to birth certificate information from
the Division of Statistics at the ND Department of Health (personal communication, Dr.
S. Pickard and C. Barth, 3/26/2015). The Pregnancy Risk Assessment Monitoring
System (PRAMS) survey of 2002 (the last year of participation by the state of North
Dakota) reported that 6.8% of the survey respondents in North Dakota had
hyperglycemia during pregnancy (DeSisto, Kim, & Sharma, 2014). DiSisto et al. (2014)
reported that there was a 9.2% prevalence of hyperglycemia during pregnancy in the
United States using PRAMS data and birth certificate information from the seventeen
states that participated in 2010. Therefore, the study findings are closely representative
of the state where the participants reside but is not representative of the nation (Figure
14).

Figure 16. Rates of hyperglycemia in the study sample compared to PRAMS results for
North Dakota and the United States. (DeSisto et al., 2014)
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Calcidiol
The serum calcidiol level is used to assess vitamin D status (Yap et al., 2014) yet
consensus has not been reached on what level of calcidiol is adequate for health (Aloia,
2011; Holick, 2007; Holick et al., 2011; Ross et al., 2011). The development of dietary
reference intakes by the Institute of Medicine (IOM) was a result of a joint effort by the
governments of the United States and Canada (Aloia, 2011). The appointed committee of
scientists reviewed the literature and based their recommendations from the evidence of
vitamin D for bone health yet determined there was insufficient evidence for causality or
a dose-response relationship for any extra-skeletal vitamin D indications (Aloia, 2011;
IOM, 2011). The IOM also concluded that a calcidiol level > 50 nmol/L is adequate and
that vitamin D inadequacy has been overestimated in North America (IOM, 2011).
Subsequently, The Endocrine Society responded by publishing a Clinical Practice
Guideline with several points of disagreement with the IOM (Hollis & Wagner, 2013;
Rosen et al., 2012) which then resulted in additional professional discourse in the
literature. The Endocrine Society Clinical Practice Guideline was developed by a task
force with input from society members and focused on prevention of vitamin D
deficiency through evaluation and treatment (Holick et al., 2011). Pramyothin and
Holick (2012) bring clarity to the differences by explaining the two organizations reflect
different views of the evidence and different goals. In the future, vitamin D studies will
guide recommendations based on patient outcomes as a result of various calcidiol levels
(Pramyothin & Holick, 2012). The Endocrine Practice Guideline recommends 600-1000
IU in pregnancy for women between 14-18 years of age and 1500-2000 IU for pregnant
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women ages 19-50 years of age (Pramyothin & Holick, 2012). The Endocrine Society
endorses a serum calcidiol of > 75 nmol/L to be adequate (Holick et al., 2011).
Recommended Daily Allowance for Calcidiol
The IOM set the recommended daily allowance for vitamin D at 600 IU daily for
persons ages 1 – 70 assuming minimal daily sunlight exposure and with no change in the
recommended daily allowance in pregnancy (Ross et al., 2011). The Endocrine Society
recommends pregnant women take at least 600 IU of vitamin D daily and recognize that
some pregnant women may need 1500-2000 IU daily to maintain adequate calcidiol
levels (Holick et al., 2011). Schwalfenberg (2007) recommends individualized dosing of
vitamin D supplements to restore serum calcidiol levels to >80 nmol/L and reported that
both insulin production and sensitivity improved from this intervention. However,
according to Schwalfenberg (2007), between 1800-2200 IU of vitamin D is needed daily
to achieve and maintain serum calcidiol levels at the target of >80 nmol/L.
Rationale for Choice of Calcidiol Level
Hollis et al. (2012) questioned if the recommendations for daily intake of vitamin
D need to change during pregnancy because optimization of the active form of vitamin D,
calcitriol, occurs only after the circulating calcidiol levels reach 100 nmol/L. The IOM
used skeletal benefits alone to develop their guidelines (Aloia, 2011; Pramyothin &
Holick 2012) while The Endocrine Society endorses a serum calcidiol level of 75 nmol/L
for the non-skeletal benefits in their published Clinical Guideline (Holick et al., 2011).
Since the influence of vitamin D for this research is for one of the non-skeletal benefits of
vitamin D, a serum calcidiol level less than 75 nmol/L was considered to be
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hypovitaminosis-D. In this study, the mean calcidiol level for VitD-early was 63.32, for
VitD-mid was 65.73, and for VitD--late) was 65.89.
Table 12. Comparison of Recommended Serum Calcidiol Levels for Pregnant Women
Ages 18-50 years.

Calcidiol status

Institute of
Medicine

NIH Office
of Dietary
Supplements

United States
Endocrine
Society

Calcidiol deficiency

< 30 nmol/L

< 30 nmol/L

< 50 nmol/L

Inadequate/insufficient

< 40 nmol/L

30-50 nmol/L

52.5-72.5
nmol/L

Considered adequate

> 50 nmol/L

> 50 nmol/L

> 75 nmol/L

No additional benefit for

> 75 nmol/L

Not applicable

Not applicable

> 125 nmol/L

> 125 nmol/L

>150 nmol/L

bone health
Potential adverse effects
Holick et al., 2011; IOM, 2011
Hypovitaminosis-D in North Dakota
Hypovitaminosis-D is of particular concern for people in North Dakota.
Researchers at the Grand Forks Human Nutrition Research Center (GFHNRC) evaluated
the diets of 224 women aged 40 years or more who had participated in a study at the
center. Based on their results, they reported the average intake of vitamin D was 135 IU
per day and concluded that most people living in the state are at risk for hypovitaminosis
D (Nielsen, 2011). The people who participate in the GFHNRC studies live in
communities near the GFHNRC and therefore are at risk for inadequate daily sunlight
exposure. Americans living in the northern latitudes do not have adequate daily exposure
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to sunlight and therefore need vitamin D supplements or fortified foods to meet the
minimum daily intake of vitamin D.
Influence of the Placenta on Calcidiol
Pregnancy is a unique physiological condition because there is a placenta and a
fetus. Physiological changes during pregnancy affect both vitamin D metabolism and
transport resulting in an increase the circulating levels of calcitriol with little effect on the
serum calcidiol levels. The mechanisms for these effects are not fully understood but
both the kidney and the placenta contribute to the increased levels of calcitriol (Brannon
& Picciano, 2011). The placenta has a functional endocrine system and is a known site
for activation of calcidiol (Anderson et al., 2014; Barrera, Avila, Hernández, & Méndez,
2008). It contains extra-renal cells which can transform calcidiol from the maternal
circulation into calcitriol. It has been proposed that the placental intervillous space could
potentially be a site for admixture of maternal circulation calcidiol and the calcitriol from
the fetal side of placental circulation (Adams & Hewison, 2012; Brannon & Picciano,
2011). It is yet unknown if this contributes to the calcitriol in maternal or fetal
circulation (Adams & Hewison, 2012). Even though serum calcidiol levels do not
increase in pregnancy, calcitriol levels gradually increase for some unknown reason,
starting at about 10-12 weeks until almost double in near the end of pregnancy (Alzaim &
Wood, 2013; Brannon & Picciano, 2011).
In laboratory studies, the overall data indicates that the human placenta not only
has the components required for vitamin D signaling, it also has the enzymes to
synthesize large amounts of calcitriol which is secreted by the placenta (Anderson et al.,
2014; Avila et al., 2004; Shin et al., 2010). In addition, the kidneys increases the
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synthesis of calcitriol during pregnancy and this higher concentration in maternal serum
which could also facilitate transfer to the fetal circulation. When calcidiol concentration
is diminished such as during vitamin D deficiency, the healthy kidney increases calcitriol
production (Adams & Hewison, 2012). These factors may contribute to the fact that the
maternal serum calcitriol levels increase until they are two-fold higher in the third
trimester than in women who are not pregnant (Parlea et al., 2011).
Calcidiol in This Study
In this study, 81% of the participants had hypovitaminosis-D at one or more
points during pregnancy and 67% had hypovitaminosis-D at all three points. It is unclear
how these findings should be interpreted because only two previous studies were
available reporting the vitamin D status for the region to compare with the findings in this
sample. Anderson et al. (2014) studied vitamin D and pregnancy outcomes found
hypovitaminosis-D in 69.5% of participants living in the same area of the Midwest.
Thiele (2014) completed research in the same region and found that 61% (8 of 13) of the
participants in the study had hypovitaminosis-D at enrollment. People who live at
latitudes higher than 37 N are especially at risk for hypovitaminosis-D because the angle
of the sun’s rays prevents adequate UVB radiation for synthesis of vitamin D through the
skin (Bodnar et al., 2007). Anderson et al. (2014) did not find that season of the year
significantly influence serum calcidiol level or pregnancy outcomes.
Serial Calcidiol Levels During Pregnancy
Few studies were found in the literature which showed serial calcidiol levels
during pregnancy which approximated the time frames in this study. Ainy, Ghazi, and
Azizi (2006) noted hypovitaminosis-D of 48 Iranian women in Tehran; yet, they did find
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that serum calcidiol levels increased as pregnancy progressed through the three
trimesters. Marwaha et al. (2011) found a high prevalence of hypovitaminosis-D
throughout the course of pregnancy for women in India. Zhao et al. (2014) found
hypovitaminosis-D in all three trimesters when retrospectively testing samples obtained
from 50 women during pregnancy in Northeast China where they did not take vitamin
supplements. Hypovitaminosis-D was prevalent at all three points in these studies
showing that the calcidiol levels did not adequately improve over time and that
hypovitaminosis D was a major problem during pregnancy (Zuhur, Erol, Kuzu, &
Altruntas, 2013). This supports the findings of Schroth et al. (2005) who stated intake of
vitamin D fortified foods or regular multivitamins may not increase the serum calcidiol to
an adequate level for maternal and fetal health. Tande et al. (2013) recommend
interventions to target the nutritional status of the mother in early pregnancy because they
provide an opportunity to improve pregnancy outcomes during this critical period for
development of both the fetus and the placenta. Improving hypovitaminosis D is of
paramount importance and readily amenable by treating with vitamin D supplements
(Alzaim & Wood, 2013; Zuhur et al., 2013).
Study Findings
In this study sample the percentage of women with hyperglycemia in pregnancy
was 5.8%. This was in spite of the level of hypovitaminosis-D, the lack of a statistically
significant change in serum calcidiol levels, and the mean BMI of 27.21 which was in the
overweight category. According to the Pregnancy Risk Assessment Monitoring System
(PRAMS) report, the rate of hyperglycemia for the state (North Dakota) was 5.1% and
for the nation was 9.2% (DeSisto et al., 2014). The percentage of women with
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hyperglycemia during pregnancy in the study sample was similar to population of the
state but not of the nation. This limits the generalizability of the study findings to the
region.
Table 13. Research Findings of Calcidiol Levels at More Than One Point in Pregnancy.
First trimester
or VitD-early

Second trimester
or VitD-mid

Third trimester
or VitD-late

Ainy, Ghazi, Azizi, 2006

51.5 nmol/L

64.3 nmol/L

71.8 nmol/L

Marwaha et al., 2011

23.4 nmol/L

25.7 nmol/L

27.7 nmol/L

Zhao et al., 2014

28.29 nmol/L

39.23 nmol/L

40.03 nmol/L

This study

63.32 nmol/L

65.7 nmol/L

65.9 nmol/L

Figure 17. Calcidiol levels at three points in pregnancy.
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Calcidiol and Blood Glucose in Pregnancy
There are conflicting findings on the influence of calcidiol on blood glucose
metabolism in pregnancy and inconsistent methodology utilized in the research. Some
investigators have reported a relationship between hypovitaminosis-D during pregnancy
and impaired glucose metabolism (Alzaim & Wood, 2013; McLeod et al., 2011; Shin et
al., 2010) or an increased risk for gestational diabetes mellitus (Aghajafari et al., 2013;
Cho et al., 2013; Parlea et al., 2011; Zhang et al., 2008 ). Other researchers report they
found an inverse relationship between vitamin D levels and fasting glucose in pregnant
women (Burris et al., 2102; Clifton-Bligh et al., 2008; Maghbooli et al., 2008;
Soheilykhah et al., 2010). In contrast, when pregnant women had mostly adequate
calcidiol levels, researchers did not find a relationship between maternal calcidiol levels
and hyperglycemia (Baker et al., 2012; Tomedi et al., 2013). Poel et al. (2012) also
completed a systematic review and meta-analysis and found a significant inverse
association between calcidiol and the incidence of impaired glucose tolerance in
pregnancy but state a causal relationship has not been proven.
In pregnancy, screening for hyperglycemia is done in mid-pregnancy as part of
routine prenatal care because the gestational steroid hormones cause a gradual increase in
peripheral insulin resistance which intensifies after mid-pregnancy (Alzaim & Wood,
2014). This acquired insulin resistance in a normal human pregnancy is estimated to be
between 40% and 70%, predominantly in the last trimester (Pridjian & Benjamin, 2010;
Retnakaran et al., 2008; Yap et al., 2014). The insulin resistance results in a significant
need for additional insulin secretion, therefore women with impaired pancreatic β-cell
reserve pre-pregnancy are at risk for developing impaired glucose metabolism such as
91

occurs in gestational diabetes (Retnakaran et al., 2008; Yap et al., 2014). The
combination of increasing insulin resistance, reduced pancreatic β-cell function, and
insufficient secretion of insulin leads to the hyperglycemia which some women
experience during pregnancy (Pridjian & Benjamin, 2010; Wang et al., 2013).
Some investigators found evidence which links hypovitaminosis-D and abnormal
glucose metabolism in pregnancy (Alzaim & Wood, 2013; Cho et al., 2013; Clifton-Bligh
et al., 2008; Pittas & Dawson-Hughes, 2010; Maghbooli et al., 2008). Asemi et al.
(2013) found that vitamin D supplementation during pregnancy had a beneficial effect on
glycemic control in women with impaired glucose metabolism. Yap et al. (2014)
investigated the effects of vitamin D supplements in either 400 IU or 5000 IU daily in
pregnant women with calcidiol < 80 nmol/L on the maternal glucose levels during an oral
glucose tolerance test at 26-28 weeks gestation. They reported that the high dose vitamin
D intervention starting at a mean of 14 weeks gestation did not improve the maternal
glucose levels (Yap et al., 2014). These two examples illustrate the inconsistent findings
noted by researchers on the relationship between vitamin D and hyperglycemia in
pregnancy (Alzaim & Wood, 2013; Collins-Fulea et al., 2012; Dror et al., 2011). Some
clarity may emerge when looking at the findings based on gestational weeks at the time
of the serum calcidiol level to see how the timing of this level relates to impaired glucose
metabolism.
Multiple Linear Regression Analysis
According to the literature, both maternal age and BMI are known confounders
for serum calcidiol levels and for hyperglycemia in pregnancy. A multiple linear
regression is a statistical model which can be used to separate the relationship of interest
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from the confounding variables (Pourhoseingholi, Baghestani & Vahedi, 2012). Because
of this, a multiple linear regression was employed to control for age and BMI in the
analysis of the relationship between calcidiol levels and BG for each of the time points.
In the analysis, calcidiol levels (VitD-early, VitD-mid, and VitD-late), BMI, and age
were the independent variables and BG was the dependent variable. The results of the
findings for each time point are discussed separately and integrated with the current
literature.
Relationship Between Calcidiol in Early Pregnancy and Blood Glucose
Is there a correlation between the calcidiol level at 10-14 weeks gestation (VitDearly) and the BG level at 24-28 weeks gestation when controlling for the known
confounding variables of age and pre-pregnancy BMI? The three participants who had
hyperglycemia at 24-28 weeks gestation had hypovitaminosis-D at VitD-early. R square
was 0.084 which means the amount of variation explained in the regression was 8.4%
indicating there does not appear to be a strong correlation VitD-early and BG at 24-28
weeks in this sample.
The current study did not find a statistically significant relationship between
calcidiol levels in early pregnancy and BG levels at 24-28 weeks gestation. These
findings are similar to Fernandez-Alonso et al. (2012) and Makgoba et al. (2011) who
both found high levels of hypovitaminosis-D in their participants yet no association with
hyperglycemia. Tomedi et al. (2013) did not find an association between calcidiol levels
at < 16 weeks gestation and BG in non-smoking women who participated in their study;
however, they did find an inverse association between first trimester calcidiol levels and
BG at 24-28 weeks gestation in participants who were smokers. Baker et al. (2013) did
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not find a relationship between calcidiol levels in early pregnancy and BG at 24-28 weeks
gestation, but a limitation of that study was the low prevalence of hypovitaminosis-D in
their participants.
In contrast, Lacroix et al. (2013) investigated calcidiol levels and insulin
resistance, and reported a modest association between first trimester hypovitaminosis-D
and insulin resistance at 24-28 weeks gestation, which suggests a higher risk for
hyperglycemia. Zhang et al. (2008) concluded that hypovitaminosis-D in early
pregnancy (< 16 weeks) was associated with an increased risk for hyperglycemia when
controlling for maternal age and BMI. They report that the women in their study who
had hyperglycemia were older and heavier than the normoglycemic women in their
sample. Parlea et al. (2011) identified cases of GDM and matched them to controls, then
analyzed frozen, stored serum samples which had been collected from those women at
15-18 weeks gestation. The groups below and above the fourth quartile for calcidiol
levels (73.5 nmol/L) were compared. They report a significant association between
calcidiol levels <73.5 nmol/L at 15-18 weeks gestation after controlling for maternal age,
BMI, and race.
The high prevalence of hypovitaminosis-D in the current study resulted in limited
variation in the sample which could have prevented evidence of a relationship between
calcidiol and BG, if one did exist. The sample sizes, methods, and early pregnancy
calcidiol levels among the research varied and these inconsistencies are a limitation when
comparing these studies. The findings in the literature are not conclusive or consistent.
To summarize these findings including the current study, there was no statistically
significant relationship found between hypovitaminosis-D in early pregnancy and BG at
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24-28 weeks gestation; however, hypovitaminosis-D possibly increases the diagnosis of
GDM.
The hypothesis for the current study was that there would be an inverse
relationship between calcidiol levels in early pregnancy and the BG level at 24-28 weeks
gestation. The state of the science does not definitively prove nor disprove this
hypothesis. Baker et al. (2012) reported that 73% of the participants in their sample had
serum calcidiol levels > 75 nmol/L which may have prevented finding the relationship
between calcidiol levels in early pregnancy and BG at 24-28 weeks gestation. Their
findings included a recommendation that research be done with participants who had a
high prevalence of hypovitaminosis-D to determine if there was a correlation between
calcidiol levels in early pregnancy and BG levels at 24-28 weeks gestation. The current
study addresses that recommendation. The sample for the current study had a high
prevalence of hypovitaminosis-D in early pregnancy and there was not a statistically
significant correlation to hyperglycemia at 24-28 weeks. Based on the current science,
there is no evidence of a statistically significant relationship between calcidiol levels in
early pregnancy and BG levels at 24-28 weeks gestation.
Relationship Between Calcidiol in Mid Pregnancy and Blood Glucose
Is there a correlation between calcidiol level at 22-26 weeks gestation (mid) and
the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI? The three the study participants who had hyperglycemia in
mid pregnancy also had hypovitaminosis-D at 22-26 weeks (VitD-mid) in addition to
early pregnancy, as noted above. The relationship between VitD-mid and BG was
analyzed controlling for maternal age and BMI with an R square of 0.071 which means
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the amount of variation explained by the model is 7.1%. There does not appear to be a
strong correlation between the calcidiol levels at VitD-mid and the BG levels at 24-28
weeks of gestation in this sample.
When compared with the early and late pregnancy, more studies have been done
in mid-pregnancy investigating the relationship between calcidiol and BG levels but there
were inconsistent findings. Most of these studies examined the relationship between
calcidiol levels and a diagnosis of GDM, which is a condition of impaired glucose
metabolism which, left untreated, leads to hyperglycemia in pregnancy. For the purposes
of this study, GDM was used as a proxy to hyperglycemia in pregnancy. The time
periods being studied varied, even though most were in the second trimester or midpregnancy. The method for the blood glucose level was inconsistent with some
researchers using a fasting BG level, others using a BG level obtained after either a onestep GDM screening test or others after a two-step GDM screening test. The calcidiol
levels used to define hypovitaminosis-D also varied in these studies.
McLeod et al. (2011) examined a subset of the HAPO study and looked at the
calcidiol level drawn concurrently as a fasting BG level at 24 to 32 weeks of gestation.
They found calcidiol levels were inversely related to the fasting BG levels which
suggests that glucose metabolism might be influenced by calcidiol. Most of their
participants were normoglycemic and there was an extremely low prevalence of
hypovitaminosis-D in their sample because of subtropical location. Zuhur et al. (2013)
obtained serum calcidiol levels when testing for impaired glucose tolerance in pregnancy
and found that only the pregnant women severely deficient for calcidiol (<12.5 nmol/L)
were at risk for hyperglycemia.
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Other researchers report an inverse association between mid-pregnancy calcidiol
and BG at 24-28 weeks gestation. Burris et al. (2012) found an inverse association
between calcidiol levels and blood glucose levels at 26-28 weeks gestation. They
reported that women with severe calcidiol deficiency (serum levels <25 nmol/L) had a
significantly increased risk of GDM. Soheilykhah et al. (2010) and Zhang et al. (2008)
found that hypovitaminosis-D in the second trimester was associated with a 2.66-fold
increase in hyperglycemia at 24-28 weeks gestation. Clifton-Bligh et al. (2008) found an
inverse correlation between calcidiol levels and fasting BG when controlling for maternal
BMI. Maghbooli et al. (2008) defined hypovitaminosis-D as serum calcidiol <25
nmol/L) with hypovitaminosis-D in 70.6% of the women which they report was
associated with insulin resistance.
The current study did not find evidence of a significant relationship between
calcidiol drawn in mid-pregnancy (22-26 weeks gestation) and the BG level at 24-28
weeks gestation when controlling for maternal age and BMI. These findings were similar
to those of Zuhur et al. (2013) who did not find a statistically significant relationship
between deficient and insufficient levels of calcidiol and impaired glucose metabolism
unless the hypovitaminosis-D was severe at < 12.5 nmol/L. Similarly, Tomedi et al.
(2013) did not find an association between calcidiol levels at < 16 weeks and
hyperglycemia in non-smoking pregnant women. As with the studies on calcidiol levels
in early pregnancy, there was variation in the collection times for the calcidiol level, the
definition of hypovitaminosis-D, and the method for obtaining the BG (fasting BG level
versus a BG level obtained after either a one-step or a two-step GDM screening test).
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The inconsistent findings across studies prevent conclusive evidence of the relationship
between hypovitaminosis-D in mid pregnancy and BG levels at 24-28 weeks gestation.
Relationship Between Calcidiol in Late Pregnancy and Blood Glucose
Is there a correlation between the calcidiol level at 32-36 weeks gestation (late)
and the BG level at 24-28 weeks gestation when controlling for the known confounding
variables of age and BMI? Two of the three participants with hyperglycemia at the GDM
screening test also had hypovitaminosis-D at 32-36 weeks gestation (VitD-late) and one
had adequate serum calcidiol at this third measurement point. The relationship between
calcidiol at 32-36 weeks gestation (VitD-late) and BG at 24-28 weeks gestation was
analyzed, controlling for maternal age and BMI. The R square was 0.075 which means
the amount of variation explained by the model is 7.5%. There does not appear to be a
strong correlation between VitD-late and BG at 24-28 weeks gestation in this sample.
This is consistent with the literature.
Three other researchers reported on the relationship between calcidiol levels and
BG levels in late pregnancy, but none of the calcidiol levels were obtained after 32 weeks
gestation. Since the current study examined the relationship between calcidiol levels at
32-36 weeks of gestation and BG, this which limits application of the study findings. For
comparison, studies which examined the relationship between calcidiol levels in the third
trimester of pregnancy and BG levels at mid-pregnancy were utilized. Farrant et al.
(2009) reported an inverse association between calcidiol levels at 30 weeks of gestation
and the blood glucose level at a 30 minute glucose screening test. Lau et al. (2011) found
that lower serum calcidiol levels in the third trimester of pregnancy were independently
associated with impaired glucose metabolism. As noted above, McLeod et al. (2011)
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found vitamin D levels were inversely related to fasting BG levels in samples drawn at
the same time from participants between 24 to 32 weeks of gestation. Based on the
current science, there is no evidence of a statistically significant relationship between
calcidiol levels in late pregnancy and BG levels in mid-pregnancy.
Limitations
This study examined the relationship between serum calcidiol levels at three
points in pregnancy and the blood glucose level at mid-pregnancy. There are several
limitations to this study. This was a correlation study and this type of research cannot
prove causation by linking exposure to outcome for individuals. It can, however, link the
association by showing a positive or negative relationship between two variables, but this
association does not prove causation (Grimes & Schultz, 2002).
Research design was influenced by the review of the literature and use of a
secondary analysis. Secondary analysis is an efficient and cost effective research design
but this method does have inherent restrictions because of the inability to change the
sample size (McArt & McDougal, 2007). It is possible that the size of the sample was
inadequate to detect the effects of hypovitaminosis-D on glucose metabolism in
pregnancy.
The participants were drawn from a geographic location that is fairly homogenous
in terms of socioeconomic status, ethnicity, and racial diversity. The participants selfselected by responding to the advertising and volunteering to be in the study. The
characteristics of pregnant women who volunteer for research studies compared to
women who do not participate in research studies are unknown for this study. Study
criteria included English speaking so it is possible that participation was limited to less
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diverse ethnic groups. Participants also needed to be at least 18 years of age so a
limitation was that the sample did not represent younger women of childbearing
potential.
The primary data set included additional information which was beyond the scope
of this study. The literature review informed the choice of variables known to influence
the outcome of interest in this population. Pre-pregnancy baseline serum calcidiol levels
were not known. The source of vitamin D intake (food, supplements, or exposure of
unprotected bare skin to direct sunlight) was not included. Factors such as season of the
year, education level, marital status, and religion were not included and are a limitation of
this study. Although these factors were of interest, they are beyond the scope of the study
reported here. Other limitations of this study are discussed further in the concluding
remarks.
Calcidiol Testing Processes
Laboratory results inform decision making therefore the accuracy and validity of
the testing process is important. Serum plasma calcidiol levels are a good biomarker for
the status of vitamin D (van den Ouweland, Beijers, Demacker & van Daal, 2010);
however, high variability has been reported in serum calcidiol measurements among
laboratories (Binkley et al., 2004). There are two main methods for determining calcidiol
levels based either on competitive immunoassay or on chromatographic separation
followed by direct detection through non-immunological means (Wallace, Gibson, de la
Hunty, Lamberg-Allardt, & Ashwell, 2010). Specificity is problematic for
immunoassays due to the proportion of 25OHD2 when quantifying the proportion of
calcidiol (Wallace et al., 2010). The methods using chromatography are more specific but
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require expensive equipment, more labor intensive, and technically more difficult
(Arneson & Arneson, 2013).
All of the discrepancies led to a new program being established in 2011, the
Vitamin D Standardization Program (VDSP). The VDSP was formed under the
combined efforts of the Center for Disease Control, National Institute of Health Office of
Dietary Supplements, National Institute of Standards and Technology, the Belgian
Laboratory for Analytical Chemistry, Ghent University, and the National Centre for
Environmental Health (Enko, Kriefshauser, Stolba, Worf, & Halwachs-Baumann, 2015).
It is anticipated that the work of the VDSP to standardize processes and emerging
automated processes will also improve precision (Arneson & Arneson, 2013).
The test used for the serum calicidiol levels for this study was the IDS 25Hydroxy Vitamin D EIA kit which uses an immunoassay method. The IDS EIA
manufacturer reports the sensitivity for their test is with 5 nmol/L (Appendix D). Care
was taken to ensure accuracy in testing, however, the validity and reliability of serum
calcidiol testing is problematic at this point in time. The availability of consistent,
specific, affordable methods is a limitation for studies involving serum calcidiol levels
such as this one.
Surprises
There were two surprises which emerged from the current study. The first was
the statistically significant impact of BMI on serum calcidiol levels in early pregnancy.
With the increasing rate of obesity in the United States, this finding highlights the need
for awareness of possible hypovitaminosis-D during pregnancy when women who
present for prenatal care have a higher BMI (Wang & Beydoun, 2007). The second was
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the lack of evidence of change in serum calcidiol levels when measured in early, mid, and
late pregnancy in this study. This is a surprise considering the focus on quality nutrition
in pregnancy including taking a daily prenatal vitamin and adequate dietary intake.
Hypovitaminosis-D may contribute to a poor foundation for life-long health therefore
further research is needed to determine how to ensure women have adequate vitamin D in
pregnancy (Kaludjerovic & Vieth, 2010). These findings suggest that prenatal vitamins
do not have adequate vitamin D. They also suggest that women with a higher BMI who
live in the upper Midwest should have a serum calcidiol level checked in early
pregnancy.
Conclusions
The current study examined the relationship between vitamin D measured as
serum calcidiol levels and the blood glucose levels in pregnancy. This research examined
the correlation between serum calcidiol and BG at three points during pregnancy. The
first was early pregnancy defined as 10-14 weeks gestation (VitD-early), the second was
mid-pregnancy defined as 22-26 weeks gestation (VitD-mid), and the third was late
pregnancy defined as 32-26 weeks gestation (VitD-late). In each case, the confounding
variables of maternal age and BMI calculated at the beginning of pregnancy were
controlled for in the multiple regression analysis. This study did not find a statistically
significant relationship between serum calcidiol levels and blood glucose levels when
controlling for the confounding variables of age and BMI at any of the three time points
in pregnancy.
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Implications for Action
Application of nursing research is an essential component to improving health.
The implications for action in response to the current study are presented here. This
begins with suggestions for nursing policy, is followed by recommendations for nursing
education, and ends with application in nursing practice. The implications for nursing
research are in the section on recommendations for further research.
Implications for Nursing Policy
Nursing evaluates the client as a system to ensure optimal wellness according to
the Neuman System Model (Neuman & Reed, 2007). Protective internal and external
mechanisms (known as Lines of Resistance) both stabilize and support the client system
(Neuman, 2005). The goal of nursing, according to the model, is to prevent or correct
instability (Meleis, 2010) through nursing interventions which improve health. The
physiological stressors of pregnancy can lead to impaired glucose metabolism for some
women. Nursing has the potential to improve the health of pregnant women by advising
them on the importance of vitamin D during pregnancy and recommending practices to
attain adequate intake of vitamin D through food sources and taking a daily prenatal
vitamin. The scope of practice for the registered nurse includes assessment of client
needs and education to meet those needs. Giving the registered nurse the skills,
knowledge and ability to prevent hypovitaminosis-D in pregnancy would be a reasonable
application of the Neuman System Model and improve health of the population.
Nurses are in a key position to influence decisions which improve health. The
findings of this study and similar studies demonstrate that hypovitaminosis-D may be a
problem for many people in North Dakota. Nurses can educate the public on the
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importance of vitamin D for health and how to get adequate amounts. Nurses can
advocate for higher levels of vitamin D supplementation and calcidiol screening.
Considering the high rates of hypovitaminosis-D, the population of pregnant women in
this region should be considered at increased risk for deficiency and screened in early
pregnancy for hypovitaminosis-D.
Implications for Nursing Education
Several implications which emerge from this research for nursing education.
Theoretically, this is an example on how the environment affects the health of patients
and demonstrates an application of the Neuman Systems Theory. Nurses need to be
aware of the importance of vitamin D within the internal environment of human body and
also be knowledgeable on sources of vitamin D from exposure to sunlight, from diet, and
from supplements (Brannon & Picciano, 2011; Specker, 2004; Tomedi et al., 2013; Ross
et al., 2011). Nursing curricula should include the unique nature of vitamin D as both a
vitamin and prohormone along with the implications for health.
Implications for Nursing Practice
Nurses are in a unique position to influence the health of mothers and their
offspring by teaching the prenatal patient about the importance of vitamin D. With
knowledge about what influences vitamin D status, the nurse can recommend testing or
additional supplementation for women at risk for hypovitaminosis-D. The nurse can
identify expectant mothers who are at risk for hypovitaminosis-D and consult with the
care team to optimize health for the women and their babies (Schroth et al., 2005). The
nurse can educate patients about the importance of adequate vitamin D during pregnancy
and inform the patients on how to safely obtain adequate vitamin D. Women of
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childbearing age could be informed of the potential health benefits that taking a
supplement with the current recommended daily allowance of 600 IU of vitamin D prior
to conception could improve serum calcidiol levels (IOM, 2011). In addition, the
findings of Ginde et al. (2010) demonstrate the need to recognize that pregnant
adolescents (ages 13-19 years) were at increased risk for hypovitaminosis-D in pregnancy
because they are more frequently are from a minority race, lower socioeconomic status,
and not using any vitamin D supplements. Nurses in practice can provide education and
support to improve vitamin D status in this at risk group.
Recommendations for Further Research
Nurse scientists are in an ideal position to study health related outcomes such as
calcidiol in pregnancy. The importance of vitamin D beyond bone health is becoming
increasingly apparent. Recent work highlights the action of vitamin D on cell
proliferation and is essential for maternal-fetal health during pregnancy and birth
outcomes (Shin et al., 2010; Hollis & Wagner, 2013). Unfortunately, the ethical concerns
of conducting research on pregnant women limits studies in this population. Careful
design must ensure no harm to either the woman or the fetus. There is a need for
rigorous intervention trials to determine if vitamin D supplementation for pregnant
women with hypovitaminosis-D status decreases the risk of hyperglycemia (Alzaim &
Wood, 2013; Baker et al., 2012; Joergensen et al., 2014; McLeod et al., 2011; Pittas &
Dawson-Hughes, 2010; Senti et al., 2013). The conflicting results on the relationship
between hypovitaminosis-D and glucose metabolism in pregnancy creates an opportunity
for nurse researchers to contribute to the science that can improve health.
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These findings suggest that epidemiological studies are needed to better
understand the regional implications of hypovitaminosis-D due to latitude, lifestyle, and
culture. There is a need for public health studies on rates of hyperglycemia in pregnancy
and comprehensive rates of GDM beyond the HAPO studies, especially because of the
implications for the lifelong health of the offspring. Since a pattern of hypovitaminosisD has been shown from various small studies at higher latitudes, larger studies are needed
to determine the prevalence of vitamin D deficiency in such populations. Finally, there is
a need to investigate the relationship between calcidiol and hyperglycemia in pregnancy
using a larger population with a greater variance in calcidiol and glucose levels.
Concluding Remarks
There are several possible reasons for results in this study. First, there may not be
an association (causal relationship) between hypovitaminosis-D and hyperglycemia in
mid-pregnancy. The high prevalence of hypovitaminosis-D in the study participants did
not provide enough variation to show a difference if one does exist. The research design
was an analysis of an existing data set which precluded increasing the sample size.
Participant characteristics closely represented the region where the participants resided
but were not representative of the nation. This limits the generalizability of the findings.
The findings of this study are consistent with the professional literature
demonstrating the hypovitaminosis-D in pregnancy is widespread and a public health
concern (Alzaim & Wood, 2013; Tande et al., 2013; Zuhur et al., 2013). A limitation of
this study is that dietary intake and vitamin use was not included in the outcome.
Presumably, a majority of pregnant women would be taking a prenatal vitamin because
this is fairly normal behavior in pregnancy. If that assumption is true, the high incidence
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and severity of hypovitaminosis-D is alarming. The women in this study were aware
they were pregnant in the first trimester because they were enrolled in the study prior to
14 weeks gestation and the sample was representative of the population, consistent in
terms of disease burden and ethnicity in the population of interest.
There was no evidence of a statistically significant relationship between the serum
calcidiol levels in early, mid, or late pregnancy and the BG level at mid-pregnancy in this
investigation. This research contributes to the science by demonstrating that serum
calcidiol levels collected in at three different points in pregnancy which were mostly
below 75 nmol/L were not associated with hyperglycemia at 24-28 weeks gestation in
pregnancy. The studies reported in the literature shows inconsistent findings on the
relationship between calcidiol and BG in pregnancy. A need exists for randomized
controlled trials to determine the effect of vitamin D supplementation on glucose
homeostasis during pregnancy (Fanos, Vierucci & Saggese, 2013; Joergensen et al.,
2014; Olmos-Ortiz et al., 2015; Senti, Thiele & Anderson, 2013). There is also a need
for further research to generate a body of evidence to determine if a change in the daily
recommended intake of vitamin D is needed to ensure adequate serum calcidiol levels in
pregnancy. This research has the potential to benefit women and offspring both during
pregnancy and for lifelong health.
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